PRIMARY RESEARCH

Open Access

Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis



Xinyi Zhang^{1,2,3}, Changsheng Xing⁴, Wenting Guan^{5,6}, Lang Chen^{4,7}, Kai Guo⁸, Anze Yu^{4,9} and Kai Xie^{4,10,11*}

Abstract

Background: Nestin has been revealed to promote tumorigenesis, progression, metastasis, and angiogenesis of breast cancer. Although the prognostic and clinicopathological impact of nestin expression on breast cancer patients has been assessed in several independent studies, their results remained conflicting. Therefore, we performed this meta-analysis to elucidate the prognostic and clinicopathological association of nestin expression with breast cancer.

Methods: A comprehensive literature search was performed in the electronic databases PubMed, EMBASE, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and the Wangfang Data. The statistical analysis was conducted using Stata 15.0 and Review Manager 5.3.

Results: A total of 15 studies with 6066 breast cancer patients were included in this meta-analysis. Pooled results indicated that positive expression of nestin was significantly associated with reduced breast cancer-specific survival (BCSS, univariate analysis, HR = 2.11, 95% CI [1.79, 2.49], P < 0.00001; multivariate analysis, HR = 1.30, 95% CI [1.06, 1.60], P = 0.01), worse overall survival (OS, univariate analysis, HR = 1.88, 95% CI [1.31, 2.71], P = 0.0007; multivariate analysis, HR = 1.89, 95% CI [1.34, 2.67], P = 0.0003) and poorer recurrence-free survival (univariate analysis, HR = 2.60, 95% CI [1.52, 4.46], P = 0.0005), but not with distant metastasis-free survival in univariate analysis (P > 0.05). In addition, increased nestin expression was correlated with younger age, higher tumor grade, larger tumor size, positive blood vessel invasion and high vascular proliferation index, but not with lymph node metastasis or lymph vessel invasion. Nestin was preferentially expressed in invasive ductal carcinoma, triple-negative breast cancer and basal-like subtypes. Nestin expression was positively correlated with the expression of ER and PR, but not with HER-2. Conversely, nestin expression was positively correlated with the presence of five basal-like profiles (BLP1-5).

Conclusions: This meta-analysis revealed the prognostic value and clinicopathological significance of nestin expression in breast cancer. Nestin is an independent prognostic factor for worse BCSS and OS of breast cancer patients. Nestin is also a valuable biomarker for unfavorable clinicopathological features and tumor angiogenesis of breast cancer. Therefore, nestin is a promising therapeutic target for malignant breast cancer, especially for TNBC and basal-like phenotype.

Keywords: Nestin, Breast cancer, Clinicopathological characteristics, Prognosis, Meta-analysis

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/

^{*}Correspondence: xiekaixy@csu.edu.cn; kxie@houstonmethodist.org ¹⁰ Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Background

Breast cancer (BC) is one of the most commonly diagnosed malignant tumors in women worldwide and the leading cause of cancer-related female mortality [1]. Primarily derived from epithelial cells of the mammary gland, BC is a heterogeneous disease with diverse histological patterns and biological features which results in distinct clinical behaviors [2, 3]. Histopathological classification of BC was primarily based on immunohistochemical (IHC) detection of four molecular markers implicated in growth signaling pathways: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki-67 [4, 5]. In accordance with different expression patterns, BC can be classified into four subtypes: luminal A (ER⁺, PR⁺, HER2⁻, low Ki-67 index), luminal B (ER⁺, PR⁺, HER2⁺ or HER2⁻, high Ki-67 index), HER2-positive (ER⁻, PR⁻, HER2⁺) and triplenegative breast cancer (TNBC, ER⁻, PR⁻, HER2⁻) [6]. Moreover, gene expression profiling can more precisely and systematically sort BC into five intrinsic molecular subtypes: luminal A, luminal B, HER2-enriched, basallike and normal-like BC [7, 8]. Among these subtypes, basal-like subtype accounts for 15% of all invasive breast cancer and is characterized by highly aggressive behaviors, poor differentiation and lack of molecular targets for endocrine and anti-HER2 therapies [7-10]. Despite the dramatical improvements in the therapeutic strategies, including surgery, radiotherapy, chemotherapy and endocrine therapy, for fighting against BC in recent years, high rates of locoregional recurrence and metastasis of malignant breast cancer, especially TNBC and basal-like subtype, still greatly threatens the physical and mental health of women [11-15]. The relatively high cost of gene expression profiling limits its application in clinical practice [16]. Thus, identification of precise, low-cost and highly accessible biomarkers to accurately diagnose BC subtypes provides a novel approach to formulating individualized treatment regimens [17–19]. As a result, it is imperative to uncover the molecular mechanisms underlying the relapse and metastasis of malignant breast cancer and explore novel therapeutic targets to improve the management of breast cancer patients [20].

Several studies have recently targeted nestin as a promising diagnostic and prognostic marker of BC [21–28]. Nestin is a type VI intermediate filament (IF) protein encoded by the *NES* gene and originally expressed in neural progenitor cells during embryonic development [29, 30]. Nestin expression is subsequently downregulated and replaced by tissue-specific IF proteins during cell differentiation in adults [31]. Apart from neural progenitor cells, nestin expression can be

detected in immature or progenitor cells in some normal tissues as well. For instance, in the normal breast tissues, nestin is expressed in the basal/myoepithelial cells of the mammary gland [32].

Extensive studies have revealed that nestin is also a putative marker for cancer stem cells (CSCs) [33-36]. CSCs are hypothetically a small subpopulation of cancer cells that possess the capacity for self-renewal as well as drive tumorigenesis and therapeutic resistance [37-39]. Aberrantly increased expression of nestin has been detected in various human malignant neoplasms, such as breast cancer [32], gliomas [35], melanomas [40], prostate cancer [36], gastrointestinal cancer [41, 42] and other cancer types [43-45]. Moreover, the prognostic value of nestin for patients with cancer has been widely validated in various solid tumors, such as epithelial ovarian cancer [46], non-small cell lung cancer [47], glioma [48, 49], etc. However, the prognostic and clinicopathological value of nestin in breast cancer patients remained controversial. Some studies have demonstrated the strong link between increased nestin expression and poor prognosis of breast cancer patients [20, 21, 23-26, 28, 50-52]. Conversely, some other studies revealed no significant association between nestin expression and survival outcomes of breast cancer patients [22, 27]. To address these discrepancies, we performed this meta-analysis to systematically determine the prognostic and clinicopathological impact of nestin on patients with breast cancer.

Materials and methods

Search strategies

Meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement [53]. A systematic literature search of the electronic databases Pub-Med, EMBASE, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and the Wangfang Data up to October 2019 was performed, without any limitation of origin and languages. The studies were identified by a random combination of the following terms: "nestin", "breast neoplasm OR breast tumor OR breast cancer OR breast carcinoma", "prognosis OR survival OR outcome". In addition, the reference lists of the retrieved studies and review articles were manually searched for potentially relevant studies.

Selection criteria

The studies included in the present meta-analysis were randomized controlled trials (RCTs) or observational studies (case–control or cohort) that evaluated the association of nestin expression with clinicopathological features or prognosis of patients with breast cancer. Studies were eligible if they met the following criteria: (a) studies were published as original articles with full text available; (b) definitive diagnosis of breast cancer was confirmed by histopathological examination; (c) nestin expression was detected by an immunohistochemistry (IHC) method or quantitative real-time polymerase chain reaction (qRT-PCR) method based on breast cancer tissues (instead of serum or other specimens), and (d) the correlation of nestin expression with clinicopathological features or prognostic outcomes was analyzed. Studies were excluded from the analyses based on the following criteria: (a) articles were published as reviews, abstracts, case reports, letters or comments; (b) studies were not associated with the topic of the interest; (c) data were obtained from cell lines or animal models; (d) data were analyzed based on public databases; (e) data for estimating the relationship between nestin expression and survival outcomes or clinicopathological features were insufficient, and (f) data were from duplicated studies based on the same or similar patient population.

Data extraction

Two investigators (XYZ and WTG) independently reviewed the included studies and extracted prognostic or clinicopathological data. Discrepancies in data extraction were resolved by a third investigator (KX). The following data were collected from each included study in a predefined table: the name of first author, year of publication, country, cancer types, number of patients, age, follow-up periods, detection method, cut-off value, clinicopathological parameters and prognostic outcomes (breast cancer-specific survival [BCSS], overall survival [OS], distant metastasis-free survival [DMFS], recurrence-free survival [RFS] and progression-free survival [PFS]). Since some studies displayed the survival data indirectly with a Kaplan–Meier curve, the software Engauge Digitizer version 12 (http://markummitc hell.github.io/engauge-digitizer/) was applied to digitize and extract survival data. Because the cut-off value for nestin expression varied among different studies, we defined the nestin-positive group according to the original articles.

Qualitative assessment

The methodological quality of included studies was assessed by two independent viewers (XYZ and WTG) using the Newcastle–Ottawa Quality Assessment Scale (NOS) (Additional file 1: Table S1). According to the guideline, NOS scores of ≥ 6 were determined to be high-quality studies.

Statistical analysis

All statistical analyses were performed by using the software Review Manager 5.3.5 (Cochrane Collaboration, Copenhagen, Denmark) and STATA 15.0 (Stata Corporation, College Station, TX, USA). The odds ratio (OR) with 95% confidence interval (CI) were calculated to assess the correlation between nestin expression and clinicopathological characteristics of breast cancer. P<0.05 were considered as statistical significance. To evaluate the prognostic effect of nestin expression on patients with breast cancer, pooled hazard ratio (HR) with 95% CI of survival outcomes were calculated. If a pooled HR is larger than 1, it reflects a worse prognosis for patients with positive nestin expression, while a pooled HR smaller than 1 represents a favorable prognosis. Heterogeneity among studies was assessed by the Chi-square (χ^2) test and I² test. When there was no significant heterogeneity (P > 0.05 or $I^2 < 50\%$), the fixed-effects model was employed; otherwise, the random-effects model was used. Sensitivity analyses were performed to examine the robustness of pooled data. Begg's and Egger's tests were conducted to assess the potential publication bias.

Results

Description of studies

Detailed steps of literature search and study selection were shown in a flow diagram [53] (Fig. 1). A total of 566 studies were initially retrieved with search strategies described above. In line with the selection criteria, 441 articles were left after duplicated records removed. After screening the titles and abstracts of identified articles, 393 articles were excluded on account of irrelevant topics, conference abstracts or cell and animal models. The remaining 48 articles were reviewed in full text, 33 articles were excluded, including 3 reviews, 29 studies without clinicopathological or survival data, and one study based on data from the public database. A total of 15 studies with were 6066 patients eventually included in the present meta-analysis. The main characteristics of eligible studies in the qualitative and quantitative synthesis were summarized in Table 1.

Correlation between nestin expression and breast cancer-specific survival

Six studies [21, 23–27] were included in the univariate analysis of the impact of nestin expression on breast cancer-specific survival (BCSS) (Table 1). As Asleh et al. [21] described, BCSS was defined as the time from diagnosis to either death by breast cancer or last follow up. The pooled result indicated that nestin expression was significantly associated with worse BCSS (pooled HR=2.11, 95% CI [1.79, 2.49], P<0.00001, I²=0%) (Fig. 2a). Moreover, three studies [23, 26, 27] investigated the correlation between nestin expression and BCSS of patients stratified by lymph node status. The pooled analysis based on univariate data showed the same result both in lymph node-negative group (pooled HR=2.59, 95% CI [1.37, 4.89], P=0.003, I²=0%) and lymph node-positive group (pooled HR=2.37, 95% CI



[1.37, 4.11], P=0.002, I²=33.6%) (Fig. 2b). Subgroup analysis of BCSS on the basis of univariate data was conducted and stratified in terms of source of data, including data directly obtained from articles and data calculated from Kaplan–Meier curves. Pooled results revealed that increased nestin expression in patients with breast cancer predicted worse BCSS in both subgroups (Direct data group: pooled HR=2.02, 95% CI [1.68, 2.43], P=0.01, $I^2 = 0\%$; Calculated data group: pooled HR = 2.48, 95% CI [1.75, 3.52], P = 0.01, $I^2 = 0\%$) (Fig. 2c). Additionally, a multivariate analysis of two studies [21, 24] demonstrated the similar result (pooled HR = 1.30, 95% CI [1.06, 1.60], P = 0.01, $I^2 = 47.4\%$) (Table 1, Fig. 2d).

Study	Year	Country	Cancer types	Cases/controls	Age (years)	Follow-up time	Method	Cut-off value (positive/ high)	Survival outcomes	Source of data	NOS score
Asleh et al. [21]	2018	Canada	IBC	339/2895	NR	12.6 years (median)	HC	A2>0	BCSS(U), BCSS(M)	Direct	∞
Asleh et al. [52]	2019	Denmark	MBC	29/216	NR	NR	HC	A2>0	OS(U), OS(M) PFS(U), PFS(M)	Direct	œ
De Lara et al. [22]	2019	Sweden	MBC	25/110	NR	10 years	IHC	A2>0	OS(U), DMFS(U) OS(M), DMFS(M)	Curve Direct	œ
Gao et al. [23]	2014	China	BC	42/109	32-79	NR	HC	A1 > 0	BCSS(U)	Curve	8
Krüger et al. [24]	2017	Norway	IBC	l: 50/47 ll: 35/244 lll: 51/130 lV: 44/143	I: 50–69 II: 50–69 III, IV: NR	I: 13 years (median) II, III, IV: NR	HC	At least 3 clearly positive cells	I: BCSS(U), BCSS(M) II, III, IV: NR	Direct	ω
Liu et al. [26]	2010	China	DCIS, IDC	24/126	27-80	NR	IHC	A5 > 0	BCSS(U)	Curve	8
Liu et al. [25]	2012	China	DCIS, IDC	62/241	NR	7.5 years	HC	A5>0	BCSS(U)	Curve	7
Meisen et al. [54]	2014	USA	BC	83/83	NR	NR	gRT-PCR	Median	DMFS(U)	Curve	7
Nowak et al. [50]	2017	Poland	IDC	109 (total)	NR	NR	HC	Nestin ⁺ MVD > 75.76 (median)	OS(U), OS(M), RFS(U)	Direct curve	7
Nowak et al. [51]	2018	Poland	IDC	39/83	NR	1–80 months	IHC	A3*B1 > 0	OS(U)	Curve	7
Parry et al. [27]	2008	UK	IBC	20/223	NR	5.2-135.3 months	HC	A5>0	BCSS(U)	Curve	8
Piras et al. [28]	2011	Italy	BC	28/25	32-67	82–194 months	IHC	A6>0	OS(U)	Curve	8
Tampaki et al. [55]	2017	Greece	BC	26/115	NR	NR	IHC	A4 > 0	RFS(U), RFS(M)	Curve direct	7
Zhao et al. [20]	2014	China	TNBC	41/109	NR	NR	HC	A1 > 0	OS(U)	Curve	7
Zhu et al. [<mark>56</mark>]	2009	China	DCIS, IDC	20/100	NR	NR	HC	A5 > 0	NR	NR	I

Table 1 Characteristics of eligible studies in the qualitative and quantitative synthesis

BC invasive breast cancer, MBC metastatic breast cancer, BC breast cancer, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, TMBC triple-negative breast cancer, BCSS breast cancer-specific survival, OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, RFS recurrence-free survival, NR not reported, U univariate analysis, M multivariate analysis

Zhao et al. [20] Zhu et al. [56] A: percentage of positive cells. A1: scored 0 (< 1%), 1 (1-9%), 2 (\geq 10%); A2: scored 0 (< 1%), 1 (\geq 1%); A3: scored 0 (0%), 1 (< 10%), 2 (10-50%), 3 (51-80%), 4 (> 80%); A4: scored 0 (\leq 5%); A5: scored 0 (< 1%), 1 (1−9%), 2 (≥ 10%); A6: scored 0 (< 10%), 1 (≥ 10%)

B: intensity of staining. B1: scored 0 (absence of staining), 1 (weak staining), 2 (moderate staining), 3 (strong staining)

Correlation between nestin expression and overall survival A pooled analysis of six studies [20, 22, 28, 50-52] reported overall survival (OS) data using univariate analysis (Table 1). With slight heterogeneity (P = 0.055, $I^2 = 53.8\%$), a random-effects model showed increased nestin expression in patients with breast cancer predicted reduced OS (pooled HR=1.88, 95% CI [1.31, 2.71], P = 0.0007) (Fig. 2e). Stratified by source of data, subgroup analysis of OS based on univariate data demonstrated that nestin expression was significantly correlated with OS in calculated data group (pooled HR = 1.76, 95% CI [1.14, 2.73], P=0.01, I^2 =49.4%), but not with OS in direct data group due to substantial heterogeneity between two included studies (pooled HR = 2.51, 95% CI [0.80, 7.88], P=0.12, I²=78.7%). Furthermore, a pooled analysis of three studies [22, 50, 52] based on multivariate data also exhibited the same result (pooled HR = 1.89, 95% CI [1.34, 2.67], P=0.0003, $I^2=26\%$) (Table 1, Fig. 2g).

Correlation between nestin expression and other survival outcomes

Two studies [22, 54] including 301 patients, investigated the correlation between nestin expression and distant metastasis-free survival (DMFS) based on univariate data (Table 1). As Lara et al. [22] described, DMFS refers to the time from the initial diagnosis of the primary breast carcinoma to distant metastasis. With moderate heterogeneity (P=0.079, I^2 =67.6%), a random-effects model showed no significant association between nestin expression and DMFS (pooled HR=1.40, 95% CI [0.74, 2.64], P=0.30) (Fig. 2h). Moreover, the study by Lara et al. [22] revealed that nestin is neither an independent prognostic factor for DMFS in multivariate analysis (HR=1.52, 95% CI [0.75, 3.06], P=0.25).

Another two studies [50, 55] with 249 patients were included in the univariate analysis of the correlation of nestin expression with recurrence-free survival (RFS) (Table 1). RFS is defined as the time from the initial diagnosis of the primary breast carcinoma to recurrence. The pooled result demonstrated that increased nestin expression predicts poorer RFS (pooled HR=2.60, 95% CI [1.52, 4.46], P=0.0005, $I^2=0\%$) (Fig. 2h). However, the study by Tampaki et al. [55] reported that nestin is not an independent prognostic factor for RFS in multivariate analysis (HR=1.238, 95% CI [0.512, 2.989], P=0.636).

In addition, Asleh et al. [52] also reported the impact of nestin expression on progression-free survival (PFS). Increased expression of nestin was associated with reduced PFS based on univariate data (HR = 1.65, 95% CI [1.04, 2.63], P = 0.03). However, no significant association was noted between nestin expression and PFS in multivariate analysis (HR = 1.26, 95% CI [0.75, 2.11], P = 0.39).

Correlation between nestin expression

and clinicopathological parameters

A total of three studies [25, 26, 56] with 590 patients investigated the association between nestin expression and age. Pooled result revealed that nestin was preferentially expressed in patients younger than 35 years old (Age > 35 vs. Age < 35, pooled OR = 0.45, 95% CI [0.26, 0.80], P = 0.006, I² = 0%) (Fig. 3a). Additionally, the study by Asleh et al. [21] including 3234 patients demonstrated that nestin expression rate was higher in patients younger than 61 years old (Age > 60 vs. Age \leq 60, OR = 0.57, 95% CI [0.45, 0.72], P < 0.00001). These results indicated nestin was closely associated with a younger age for the onset of BC.

To confirm the correlation between nestin expression and TMN staging (histological grade, tumor size and lymph node status), a pooled analysis of thirteen datasets from ten studies [21–28, 55, 56] showed that nestin expression was significantly associated with higher tumor grade (grade III vs. grade I–II, pooled OR=4.90, 95% CI [2.73, 8.79], P<0.00001, I²=84%) (Fig. 3b) and larger tumor size (T>2 cm vs. T<2 cm, pooled OR=1.30, 95% CI [1.09, 1.55], P=0.004, I²=35%) (Fig. 3c), but not with lymph node metastasis (N₊ vs. N₀, pooled OR=0.99, 95% CI [0.69, 1.42], P=0.96, I²=64%) (Fig. 3d).

Nestin has recently drawn attention as a marker for tumor angiogenesis. Eight datasets from five studies [21, 23, 24, 26, 27] were included in investigating the correlation of nestin expression with three angiogenesis-related variables blood vessel invasion (BVI), lymph vessel invasion (LVI) and vascular proliferation index (VPI). As Krüger et al. [24] described, VPI was defined as the proportion of vessels with proliferating endothelial cells. Pooled results demonstrated that nestin expression was significantly associated with positive BVI (pooled OR = 2.60, 95% CI [1.36, 4.97], P = 0.004, I² = 0%) (Fig. 3e) and high VPI (pooled OR = 3.00, 95% CI [1.91, 4.71], P < 0.00001, I² = 0%) (Fig. 3f), but not with LVI

(See figure on next page.)

Fig. 2 Forest plots of the correlation of nestin expression with survival outcomes. **a** The correlation of nestin expression with BCSS in univariate analysis; **b** The correlation of nestin expression with BCSS stratified by lymph node status in univariate analysis; **c** Subgroup analysis of BCSS based on univariate data stratified by source of data; **d** The correlation of nestin expression with BCSS in multivariate analysis; **e** The correlation of nestin expression with OS in univariate analysis; **f** Subgroup analysis of OS based on univariate data stratified by source of data; **g** The correlation of nestin expression with DMFS and RFS in univariate analysis



a	Ago > 25	A	-		Odde Patia	0.11	Patio
Study or Subgroup	Events Total	Events T	o Fotal W	eight M-	H, Fixed, 95% Cl	M-H, Fixe	d, 95% CI
Liu CG et al 2010 Liu CG et al 2012	22 136 45 272	2 17	14 1 48 7	10.0% 79.5%	1.16 [0.24, 5.54] 0.36 [0.18, 0.71]		
Zhu J et al 2009	18 113	2	7 1	10.4%	0.47 [0.09, 2.63]		
Total (95% CI) Total events	521 85	21	69 10	00.0%	0.45 [0.26, 0.80]	•	
Heterogeneity: $Chi^2 = 1$ Test for overall effect: 7	82, df = 2 (P)	= 0.40); I ²	= 0%		0	01 0.1	10 100
b	Grade III	Grade I	-11		Odds Ratio	Favours [Age>35]	Favours [Age<35] Ratio
Study or Subgroup	Events Tota	Events	Total W	eight M-H	H, Random, 95% Cl	M-H, Rand	om, 95% Cl
Gao NN et al 2014	8 20	y 78 0 33	89	9.1%	1.13 [0.42, 3.05]		<u> </u>
Krüger K et al-II 2017 Krüger K et al-II 2017	22 64	4 13	215	10.1%	8.14 [3.80, 17.44]		
Krüger K et al-III 2017 Krüger K et al-IV 2017	41 80	7 13	89	9.6%	2.75 [1.33, 5.68]		
Liu CG et al 2010 Liu CG et al 2012	43 132	2 19	114	7.5% 51 10.9%	4.30 [2.36, 7.81]		
Parry S et al 2008 Piras F et al 2011	20 109 6 19	9 0 5 22	63 38	3.2% 2 8.0%	9.09 [1.73, 489.88] 0.48 [0.14, 1.64]		
Tampaki EC et al 2017	20 81	1 5	53	8.8%	3.15 [1.10, 9.00]		
Total (95% CI) Total events	496	210	2801 10	00.0%	4.90 [2.73, 8.79]		-
Heterogeneity: Tau ² = 0.7 Test for overall effect: Z =	72; Chi² = 63.9 = 5.33 (P < 0.00	5, df = 10 (0001)	(P < 0.00	001); I ² = 8	84%	0.01 0.1 Favours [Grade III]	1 10 100 Favours [Grade I-II]
C	T2-4	T	Т1		Odds Ratio	Odd	s Ratio
Study or Subgroup Asleh K et al 2017	Events To 172 15	otal Event 533 16	ts Total 6 1687	Weight 65.5%	M-H, Fixed, 95% C 1.16 [0.92, 1.45	I M-H, Fi:]	ked, 95% Cl
Krüger K et al-I 2017 Krüger K et al-II 2017	22 1	169 2 74 2	28 359 20 205	7.3%	1.77 [0.98, 3.20]	<u> </u>
Krüger K et al-III 2017	32	92 1	17 81	5.5%	2.01 [1.01, 3.99		<u> </u>
Liu CG et al 2010 Liu CG et al 2012	55 2	266	4 31 7 54	4.3%	1.36 [0.43, 4.33]	<u>+</u>
Parry S et al 2008 Tampaki EC et al 2017	10 13	87 1 89 1	LO 89 L2 48	4.1% 6.2%	1.03 [0.40, 2.60 0.51 [0.21, 1.24		+
Zhu J et al 2009	19 1	102	1 18	0.6%	3.89 [0.49, 31.07] —	
Total (95% CI) Total events	358	5 31 26	2572	100.0%	1.30 [1.09, 1.55	1	•
Heterogeneity: Chi ² = 1	2.22, df = 8 (F	P = 0.14); I	$I^2 = 35\%$			0.01 0.1	1 10 100
d	2 = 2.89 (P = 0).004)	•			Favours [T2-4] Favours [T1]
Study or Subgroup	Events To	tal Events	s Total	Weight M	M-H, Random, 95%	CI M-H, Rar	idom, 95% Cl
Asleh K et al 2018 De Lara S et al 2019	137 15 12	96 232 65 9	2 2029 9 46	15.4% 7.6%	0.73 [0.58, 0.9 0.93 [0.36, 2.4	1] · ·	-
Krüger K et al–I 2017 Krüger K et al–II 2017	15 1 14	41 35 94 21	5 382 1 184	10.8% 9.8%	1.18 [0.62, 2.2 1.36 [0.66, 2.8	3] 1]	*
Krüger K et al-III 2017	9	59 25 53 12	5 60	8.3% 8.3%	0.25 [0.10, 0.6	1j ——	L
Liu CG et al 2012	46 1	92 16	5 128	11.0%	2.21 [1.19, 4.1	D]	
Piras F et al 2011	22	41 6	5 12	5.3%	1.16 [0.32, 4.2	0]	
Tampaki EC et al 2017 Zhu J et al 2009	11 9	59 14 48 11	1 78 1 72	8.3% 7.5%	1.05 [0.44, 2.5 1.28 [0.49, 3.3	7] –	—
Total (95% CI)	24	56	3151	100.0%	0.99 [0.69, 1.4	2]	+
Total events Heterogeneity: Tau ² = 0	296 1.21; Chi ² = 28	392 02, df = 1.	2 .0 (P = 0.	002): 12 =	C 40/		
Test for overall effect: Z	0.05 (0.0				04%	0.01 0.1	1 10 100
•	= 0.05 (P = 0.	.96)			04%	0.01 0.1 Favours [N-	i 10 100 -] Favours [N0]
e Study or Subgroup	BVI positive Events Total	.96) BVI negat Events	tive Total W	eight M-H	04% Odds Ratio H, Fixed, 95% Cl	0.01 0.1 Favours [N- Odds F M-H, Fixed	i 10 100 -] Favours [N0] atio , 95% CI
E Study or Subgroup Krüger K et al-I 2017 Krüger K et al-II 2017	BVI positive Events Total 6 29 10 43	96) BVI negat Events 14 25	tive Total W 158 236	/eight M-H 36.8% 2 63.2% 2	04% Odds Ratio H, Fixed, 95% Cl 2.68 [0.94, 7.69] 2.56 [1.13, 5.81]	0.01 0.1 Favours [N- Odds R M-H, Fixed	1 10 100 -] Favours [N0] atio , 95% CI
E Study or Subgroup Krüger K et al-I 2017 Krüger K et al-II 2017 Total (95% CI)	BVI positive <u>Events</u> Total 6 29 10 43 72	96) BVI negat Events 14 25	tive Total W 158 236 394 10	(eight M-H 36.8% 2 63.2% 2 00.0% 2	04% Odds Ratio H, Fixed, 95% Cl 2.68 [0.94, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97]	0.01 0.1 Favours [N- Odds R M-H, Fixed	i 10 100 -] Favours [N0] atio .95% Cl
C Study or Subgroup Krüger K et al-l 2017 Krüger K et al-ll 2017 Total (95% CI) Total events Heterogeneity: Chi ² = 0.00	BVI positive <u>Events</u> Total 6 29 10 43 72 0, df = 1 (P = 0	96) BVI negat Events 14 25 39 .94); I ² = 09	tive <u>Total W</u> 158 236 394 10 %	Veight M-H 36.8% 2 63.2% 2 00.0% 2	04% Odds Ratio H, Fixed, 95% Cl 2.68 [0.94, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97]	0.01 0.1 Favours [N- Odds R M-H, Fixed	1 10 100 -] Favours [N0] atio
C Study or Subgroup Krüger K et al-12017 Krüger K et al-112017 Total (95% CI) Total events Heterogeneity: Chi ² = 0.0 Test for overall effect: Z = f	BVI positive <u>Events</u> Total 6 29 10 43 72 16 0, df = 1 (P = 0 = 2.90 (P = 0.00	96) BVI negat Events 14 25 .94); I ² = 09 4)	tive <u>Total</u> W 158 236 394 10 %	(eight M-H 36.8% 2 63.2% 2 00.0% 2	04% Odds Ratio H, Fixed, 95% CI 2.68 [0.94, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97]	0.01 0.1 Favours [N- Odds F M-H, Fixed 0.1 Favours [8VI positive]	1 10 100 1 Favours [N0] atio 95% CI 10 avours [8VI negative]
E Study or Subgroup Krüger K et al-1 2017 Krüger K et al-11 2017 Total (95% CI) Total events Heterogeneity: Chi ² = 0.01 Test for overall effect: Z = f Study or Subgroup	Events Total 6 29 10 43 0, df = 1 (P = 0.00 VPI high Events Total 72 16 0, df = 1 (P = 0.00 VPI high	96) BVI negat Events 14 25 .94); I ² = 09 4) VPI I tal Events	tive Total W 158 236 394 10 % low s Total	Veight M-H 36.8% 2 63.2% 2 00.0% 2	Odds Ratio H, Fixed, 95% CI 2.68 [0.94, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97] 0.01 Odds Ratio M-H, Fixed, 95% CI	0.01 0.1 Favours [N- Odds F M-H, Fixed - 0.1 Favours [BVI positive] 1 Odd M-H, Fix	1 10 100 -] Favours [N0] atio 95% CI
Budy or Subgroup Study or Subgroup Krüger K et al-1 2017 Krüger K et al-11 2017 Total (95% CI) Total events Heterogeneity: Chi ² = 0.0 Test for overall effect: Z = f Study or Subgroup Krüger K et al-1 2017	Events Total 6 29 10 43 72 16 0, df = 1 (P = 0.00 VPI high Events Total 9 22	96) BVI negat Events 14 25 .94); I ² = 09 4) VPI I tal Events 44 11 47 20	tive <u>Total</u> W 158 236 394 10 % low s Total 133 30 130	(eight M-H 36.8% 2 663.2% 2 00.0% 2 Weight I 21.7% 40.9% 2%	Odds Ratio H, Fixed, 95% CI 2.68 [0.94, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97] ↓ Odds Ratio M-H, Fixed, 95% CI 2.85 [1.09, 7.43] 3.06 [1.5 6.21]	0.01 0.1 Favours IN- M-H, Fixed - - - - - - - - - - - - - - - - - - -	1 10 100 1 Favours [N0] atio atio atio atio 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Krüger K et al-1 2017 Krüger K et al-11 2017 Total (95% CI) Total events Heterogeneity: Chi ² = 0.0 Test for overall effect: Z = f Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1012 Krüger K et al-1012 Krüger K et al-1012 Krüger K et al-1012	= 0.03 (P = 0. BVI positive Events Total 6 29 10 43 72 16 0, df = 1 (P = 0.00 VPI high Events Total 9 0.00 22 19	96) BVI negat <u>Events</u> 14 25 39 94); I ² = 09 4) VPI I tal Events 44 11 47 29 46 24	tive <u>Total</u> W 158 236 394 10 % low 5 Total 133 3 130 4 127	Weight M-H 36.8% 2 63.2% 2 00.0% 2 Weight M 21.7% 40.9% 37.4% 37.4%	04% Odds Ratio 1, Fixed, 95% CI 2.56 [0.34, 7.69] 2.56 [1.13, 5.81] 2.60 [1.36, 4.97] 0.00 Odds Ratio M−H, Fixed, 95% CI 2.85 [1.09, 7.43] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 3.02 [1.45, 6.31]	0.01 0.1 Favours IN- Odds R M-H, Fixed Favours (BVI positive) I Favours (BVI positive) I Odds M-H, Fix	1 10 100 1 Favours [N0] 100 atio atio 395% C1 10 100 100 100 100 100 100 10
Budy or Subgroup Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% CI) Test for overall effect: 2 = f Study or Subgroup Krüger K et al-1 2017 Total (95% CI)	Events Total 6 29 10 43 72 16 0, df = 1 (P = 0 • 2.90 (P = 0.00 VPI high Events Tot 9 9 22 19 11 12 13 14 19 10 10 10 10 10 10 10 10 10 10	9:96) BVI negat Events 14 25 39 9:94); I ² = 09 VPI I tal Events 44 11 47 29 46 24 37	tive Total W 158 236 394 10 % Iow s Total 133 9 130 4 127 390	Weight M-H 26.8% 2 00.0% 2 Weight 1 21.7% 40.9% 37.4% 100.0%	0495 Odds Ratio 4, Fixed, 95% C1 5.68 (0.94, 7.69) 5.56 (1.13, 5.81) 5.60 (1.36, 4.97) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.85 (1.09, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71)	0.01 0.1 Odds B M-H, Fixed	1 10 100 1 Favours [N0] atio 95% Cl avours [8V] negative] 10 100 100 100 100 100 100 100
Exudy or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% CI) Total (95% CI) Total events Heterogeneity: Chi ² = 0.0 Test för overall effect: Z = f Study or Subgroup Krüger K et al-1 2017	= 0.05 (P = 0. BVI positive Events Total 6 29 10 43 72 16 0, df = 1 (P = 0 • 2.90 (P = 0.00 VPI high Events Tot 9 22 19 11 50 0.01, df = 2 (P =	9.96) BVI negat <u>Events</u> 1 14 25 .94); I ² = 09 VPI I tal Events 44 11 47 29 46 24 37 64 = 0.99); I ² =	tive <u>Total W</u> 158 236 394 10 % 100 5 <u>Total</u> 133 3130 4 127 390 4 = 0%	Weight M-H 26.8% 2 63.2% 2 00.0% 2 Weight 1 21.7% 40.9% 37.4% 100.0%	0*% Odds Ratio H, Fixed, 95% C1 .56 (0.94, 7.69) .56 (1.13, 5.81) .60 (1.36, 4.97) .60 (1.36, 4.97) .60 (1.36, 4.97) .00 Odds Ratio M-H, Fixed, 95% C1 .265 (1.09, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71]	0.01 0.1 Favours IN- M-H, Fixed 0.1 Favours (BVI positive) I M-H, Fix	1 10 100 1 Favours [N0] atio 395% Cl 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2017 Total (95% C) Total (95% C) Total (95% C) Total (95% C) Study or Subgroup Krüger K et al-1 2017	= 0.05 (P = 0. BVI positive <u>Events</u> Total 6 29 10 43 72 16 0, df = 1 (P = 0 2.90 (P = 0.00 VPI high <u>Events</u> Tot 9 9 12 50 0.1, df = 2 (P = 4.79 (P < 0.	9.96) BVI negat <u>Events</u> 1 14 25 39 94); I ² = 09 VPI II tal Events 44 11 47 29 46 24 37 64 = 0.99); I ² = 00001)	tive <u>Total</u> W 158 236 394 10 % low <u>s Total</u> 133 9 130 4 127 390 4 = 0%	Weight V 21.7% 40.9% 37.4% 100.0%	Odds Ratio H, Fixed, 95% C1 2.68 (0.04, 7.69) 2.66 (0.44, 7.69) 6.00 (1.36, 4.97) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.85 (1.09, 7.43) 3.06 (1.51, 6.21) 3.02 (1.45, 6.31) 3.00 (1.91, 4.71]	0.01 0.1 Favours IN- M-H, Fixed 0.1 Favours (BVI positive) 1 M-H, Fix M-H, Fixed M-H, Fix	1 10 100 1 Favours [N0] atio 395% Cl 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2017 Total (95% CI) Total e05% CI Total e05% CI Total e05% CI Total e05% CI Test for overall effect: 2	BVI positive Events Total 6 29 10 43 16 6 29 10 43 72 0, df = 1 (P = 0. 2.90 (P = 0.00 VPI high Events Tot 9	96) BVI negat Events 1 14 25 	tive Total W 158 236 394 10 % low <u>s Total</u> 133 9 130 4 127 390 4 = 0% regative tr Total	Weight V 21.7% 40.9% 37.4% 100.0%	Odds Ratio <u>4</u> , Fised, <u>95% C1</u> <u>268</u> (0.04, 7.69) <u>256</u> (1.13, 5.81) <u>160</u> (1.36, 4.97) <u>0</u> , <u>0</u>	0.01 0.1 Favours IN- M-H, Fixed 0.1 1 Favours (BVI positive) 1 Godd M-H, Fix Odd M-H, Fix	1 10 100 1 Favours [N0] atio atio atio 10 100 100 100 100 100 100 100
E Study or Subgroup Kruger K et al-1 2017 Kruger K et al-1 2017 Kruger K et al-1 2017 Total (95% CI) Total e05% CI) Study or Subgroup Study or Subgroup Study or Subgroup		96) BVI negat <u>Events</u> 14 25 	tive Total W 158 236 1 394 10 % low <u>s Total</u> 1 133 9 130 4 127 390 4 227 390 4 27 390 4 26 10% s Total 5 10% 10% 10% 10% 10% 10% 10% 10%	Weight M-H 36.8% 2 63.2% 2 00.0% 2 Weight 40.9% 37.4% 100.0% al Weight 8 76.2%	Odds Ratio H, Fixed, 95% Cl 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio 0.01 0.02 0.03 0.04 0.05, 1.03 0.02 0.05, 1.03 0.05 0.0	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours (8V) positive) 1 Favours (8V) positive) 1 Godd M-H, Fix Odd M-H, Fix Odd M-H, Fix 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	1 10 100 1 Favours [N0] atio 9% C1 10 100 10 10 10 10 10 10 10 10 10
Study or Subgroup Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total vernts Heterogeneity: Ch² = 0.0 Test för overall effect: 2 = f Study or Subgroup Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total (95% C) Total (95% C) Study or Subgroup	$\begin{array}{c} 0.05 \ (r=0.017) \\ \hline & EVents & Total \\ \hline & & & & \\ \hline & & & & \\ \hline & & & & \\ \hline & & & &$	9.96) BVI negat <u>Events</u> 14 25 39 .94); I ² = 09 4) VPI I tal Events 44 11 47 29 46 24 37 644 = 0.99); I ² = 00001) e LVI n otal Events 412 12 19 412 29 42 1	tive Total W 158 236 394 10 % Iow 5 Total 133 9 130 4 127 390 4 127 390 4 226 6 168 6 6 168 6 6 16	Weight M-H 36.8% 2 63.2% 2 00.0% 2 Weight 7 40.9% 37.4% 100.0% 37.4% 8 76.2% 8 76.2% 5 3.1%	Odds Ratio +, fixed, 95% C1 2.68 [0.04, 7.69] 2.68 [0.04, 7.69] 2.68 [1.36, 4.97] 0.00 Odds Ratio M-H, Fixed, 95% C1 2.85 [1.09, 7.43] 3.06 [1.51, 6.21] 3.00 [1.91, 4.71] Odds Ratio 1. M-H, Fixed, 95% C1 0. 0.83 [0.63, 1.0 0. 0.33 [0.627, 2.6 0. 0.38 [0.6727, 2.6 0. 0.85 [0.272, 7.6] 0. 0.	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 - Favours (NP positive) 1 Favours (NP positive) 1 Godd M-H, Fix 0dd M-H, Fix 0dd 0dd M-H, Fix 0dd 0dd M-H, Fix 0dd 0dd 0dd 0dd 0dd 0dd 0dd 0d	1 10 100 1 Favours [N0] atio 95% Cl avours [8V] negative] 100 avours [8V] negative] 100 Favours [VPI low] 100 Favours [VPI low] 100 Favours (VPI low] 100 Favours (VPI low] 100 Favours (VPI low] 100
B Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% CI) Total (95% CI) Total (95% CI) Total vents Heterogeneity: Chi² = 0.0 Test for overall effect: Z = f Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-2017 Kotager K et al-2017 Kröger K et al-2017 Kotager K et al-2017 Kröger K et al-1 2017 Kröger K et al-2017 Kröger K et al-2018 Gao NN et al 2018 Gao NN et al 2018 Gao NN et al 2017 Krüger K et al-2017 Krüger K et al-2017	■ 0.05 (F = 0. ■ 0.05 (F = 0. ■ Not positive ■ Not positive ■ 0 0 2 16 0 0. df = 1 (P = 0 2.90 (P = 0.00) 2.90 (P = 0.00) 10 2.20 11 12 10 10 11 10 11 10 11 12 13 14 15 14 15 15	96) BVI negat <u>Events</u> 14 25 39 94); I ² = 09 4) VPI I tal Events 44 11 47 29 46 24 37 644 25 00001) e LVI n 50001 e LVI n 500001 e LVI n 5000001 e LVI n 50000001 e LVI n 5000000000000000000000000000000000000	tive Total W Total II Total II Total II Total II Total Total II	Weight M-H 36.8% 2 53.2% 2 00.0% 2 Weight N 21.7% 40.9% 37.4% 100.0% al Weight 8 76.2% 8 76.2% 9 5.1% 9 5.1%	Odds Ratio H, Fixed, 95% C1 2:68 (0.04, 7.69) 2:68 (0.04, 7.69) 2:68 (0.04, 7.69) 0:00 Odds Ratio M-H, Fixed, 95% C1 2:85 (1.03, 7.43] 3:00 (1.51, 6.21] 3:00 (1.51, 6.21] 4:00 (1.52, 52) 0:03 (0.42, 2.0 0:03 (0.42, 2.0 0:03 (0.42, 2.0 0:03 (0.42, 2.0) 0:03 (0.01 0.1 Favours IN- Odds B M-H, Fixed 0.1 Favours (BVI positive) I Favours (VPI high Favours (VPI high Gud M-H, Fix Odd M-H, Fix 0.1 Favours (VPI high Gud M-H, Fix 0.1 Favours (VPI high Gud M-H, Fix 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	1 10 100 1 Favours [N0] 100 100 100 100 100 100 100 1
E Study or Subgroup Study or Subgroup Kroger K et al-1 2017 Kroger K et al-1 2017 Study or Subgroup Total (95% C) Total (95% C) Total events Heterogeneity: Chi² = 0.0 Test for overall effect: Z = f Study or Subgroup Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-2 (17 Kröger K et al-1 2017 Kröger K et al-2 (17 Kröger K et al-2 (12 Kröger K et al-2 (12 N kröger K et al-1 (12 N 1 kröger K et al-1 (12 N 1 1 kröger K et al-1 (12 N 1 1 kröger K et al-1 (12 N 1 1 1 kröger K et al-1 (12 N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.05 (P = 0. BVI positive Events Total 6 29 (2) 16 72 0. df = 1 (P = 0. 2.90 (P = 0.00) 2.90 (P = 0.00) 2.90 (P = 0.00) 9 2 10 19 10 11 50 11 11 50 12 12 19 10 11 50 11 11 10 12 14 13 14 14 15 13 11 13 11 11	9:66) BVI negat Events 39 9:41 25 39 9:41 29 20 20 20 20 20 20 20 20 20 20 20 20 20	Total W Total 158 158 236 236 394 10 5 5 Total 4 133 9 130 4 390 6 168 6 168 6 168 6 168 6 168 6 168 6 14 0 118 9 6	Image: Control of the system Image: Control of the system 36.8% 2 36.8% 2 263.2% 2 Weight 7 21.7% 40.9% 37.4% 100.0% 100.0% 3 al Weight 8 76.2% 8 76.3% 9 5.1% 8 4.8% 0 5.0%	Odds Ratio H, Fixed, 95% C1 2:68 (0:04, 7:69) 2:68 (0:04, 7:69) 2:68 (1:04, 7:69) 0:00 0:00 0:00 0:00 0:00 0:00 0:00 0:	0.01 0.1 Favours IN- 0.01 0.1 Favours IN- 0.1 - Favours IV- 0.01 0.1 Favours IV- 0.	1 10 100 1 Favours [N0] atio 95% Cl 10 100 100 100 100 100 100 100
E Study or Subgroup Kruger K et al-1 2017 Kruger K et al-1 2017 Kruger K et al-1 2017 Total (95% CI) Total events Heterogeneity: Ch ² = 0.0 Test for overall effect: 2 = f Study or Subgroup Krüger K et al-1 2017 Total events Heterogeneity: Ch ² = 0.0 Gon Nt et al 2018 Gon Nt et al 2014 Krüger K et al-1 2017 Stelk for al 2014 Krüger K et al-1 2017 Dard events Stelk for al 2018 Gon Nt et al 2018 Stelk for al 2014 Krüger K et al-1 2017 Jury S et al 2018 Stelk for al 2018 Krüger K et al-1 2017 Jury S et al 2018 Stelk for al 2018 Stelk for al 2018 Heterogeneity Stelk f	$ \begin{array}{c} 0.05 \ (r=0. \\ 0.01 \ (r=0. \ (r=0. \\ 0.01 \ (r=0. \ (r=0.$	9:66) BVI negat Events 14 25 39 9:41; 1 ² = 09 41 VPI I 44 11 47 29 44 11 47 29 44 11 47 29 40 00001) e LVI n 5tal Event 11 2 12 19 41 2 82 1 15 782	tive Total W Total 158 1236 13 236 1 168 16 s 3394 10 1 % Total 133 130 1 133 130 130 4 0 188 6 6 168 168 6 6 6 14 1 10 18 9 6 9 6 221 6	Weight I 36.8% 2 53.2% 2 00.0% 2 Weight 1 21.7% 40.9% 37.4% 100.0% al Weight 8 76.2% 8 5.8% 5 3.1% 9 5.13% 8 4.8% 0 5.0% 8 100.0%	Odds Ratio H, Hsed, 95% C1 2.68 (0.04, 7.69) 2.56 (1.33, 5.81) .660 (1.36, 4.97) 0.07 0.04ds Ratio M-H, Fixed, 95% C1 3.06 (1.51, 6.21) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71) 0.045 Ratio M-H, Fixed, 95% 4.030 (0.63, 1.04) 0.033 (0.42, 2.0 4.159 (0.82, 3.4 4.038 (0.41, 2.3) 5.068 (0.127, 1.5) 5.088 (0.47, 1.3)	0.01 0.1 Favours IN- 0.01 0.1 Favours IN- 0.1 1 Favours IVPI positive1 0.01 0.1 Favours IVPI high 0.01 0.1 Favours IVPI hig	1 10 100 1 Favours [N0] atio 395% Cl 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2017 Kringer K et al-1 2017 Total (95% CI) Total e05% CI) Total e05% CI) Total e05% CI) Total events Heterogeneity: Chi ² = 0.0 Krüger K et al-1 2017 Krüger K et al-1 2017 Total events Heterogeneity: Chi ² = 0.0 Study or Subgroup Asleh K et al 2018 Krüger K et al-1 2017 Total events Heterogeneity: Chi ² = 0.0 Study or Subgroup Asleh K et al 2018 Krüger K et al-1 2017 Krüger K et al-1 2017 Total events Heterogeneity: Chi ² = 4	Boy and the set of the set	9:66) BVI negat Events	tive Total W 158 236 3 394 14 % bow s Total 1 1 133 3 4 127 390 4 4 0% box box box box box box box box box box	Weight I 21,7% 40,9% 37,4% 100,0% 2 37,4% 100,0% 2 8 58,2% 9 5,13 9 5,13 9 5,13 8 4,80 8 5,83 8 100,0%	Odds Ratio H, Fixed, 95% Cl 2.68 [0.94, 7.69] 2.68 [0.94, 7.69] 2.68 [0.94, 7.69] 0.00 Odds Ratio M→H, Fixed, 95% Cl 2.65 [1.09, 7.43] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 3.06 [1.51, 6.21] 0.05 [0.63, 1.0 0.05 [0.27, 2.6 0.05 [0.27, 2.6 0.05 [0.27, 2.5 0.05 [0.70, 1.0 0.05 [0.70, 1.0	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours [W] positive] 1 Favours [W] positive] 1 0dd M-H, Fix 0dd M-H, Fixed 0dd M-H, Fixed 0dd M-H, Fixed 0dd M-H, Fixed 0dd M-H, Fixed 0dd 0dd M-H, Fixed 0dd 0dd M-H, Fixed 0dd 0dd M-H, Fixed 0dd M-H, Fixed 0dd 0dd M-H, Fixed 0dd 0dd M-H, Fixed 0dd 0dd 0dd 0dd 0dd 0dd 0dd 0	1 Favours [N0] 100 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2017 Kringer K et al-1 2017 Total (95% CI) Study or Subgroup Krüger K et al-1 2017 Total (95% CI) Study or Subgroup Krüger K et al-1 2018 Gao NM et al 2018 Gao NM et al 2018 Krüger K et al-1 2017 Krüger K et al-1 2017 Total events Heterogeneity: Chi² = 0. Krüger K et al-1 2018 Gao NM et al 2018 Krüger K et al-1 2017	= 0.05 (° = 0. BVI positive <u>Events Total</u> 6 29 10 43 72 0, df − 1 (° − 0. 2. 2.9 (° − 0. 0 - 2. 2.9 (° − 0. 0 - 2. 2.9 (° − 0. 0 - 2. 9 (° − 0. 10 - 2. 9 - 2. 10 - 2.	96) BVI exerts 	tive tive 158 394 10 3394 10 394 10 $\frac{5}{10}$ $\frac{5}{10}$ 390 4 127 $\frac{390}{16}$ $\frac{4}{101}$ 133 90 4 126 $\frac{6}{168}$ 6 16 14 11 6 19 6 168 11 6 19 6 188 9 6 127 78 221 78 20% 78 20% 221 78 20% 78 20% 78 20% 221 78 20% 78 20% 78 20% 221 78 20% 78 20% 20% 22 22 22 22 20%	Weight M-1 36.8% : 36.8% : 36.8% : 21.7% : 40.96 : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% : 100.0% :	Odds Ratio H, Fixed, 95% Cl 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% Cl 2.65 (1.90, 7.43) 3.06 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio M-H, Fixed, 95% Cl 0.083 (0.63, 1.0 0.085 (0.72, 2.6 0.098 (0.41, 2.3 0.085 (0.70, 1.0	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (VPI high 0.01	1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10
Bit Study or Subgroup Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2017 Total (95% C) Total or Subgroup Kringer K et al-1 2017 Total (95% C) Total (95% C) Study or Subgroup Kringer K et al-1 2017 Kringer K et al-1 2018 Gao NH et al 2018 Gao NH et al 2018 Total 2018 Heterogeneity: Chi ² 4 Linger K et al-1 2017 Total 2018 Total 2018 Ketorgeneit 2010 <	Events Total Events Total Events Total Events Total Comparison Compari	96) BVI negat Pertext 14 25 39 949; I ² = 00 VPI 141 Events 144 47 29 29 20 20 20 20 20 20 20 20 20 20	tive trol W 158 236 394 10 394 10 3394 10 % Total 133 390 14 127 394 127 390 4 127 390 4 20% Total 166 6 6 6 6 14 10 18 19 6 6 6 14 10 18 19 6 221 7 8 20% 221 23 20 221 23 20 22 1 30 10	eight M (6 (6 (6 (7 (7 (7 (7 (7 (7 (7 (7	Odds Ratio +, fixed, 95% C1 ≥68 [0.34, 7.69] ≥68 [0.34, 7.69] ≥69 [0.34, 7.69] ≥60 [1.36, 4.97] 000 Odds Ratio M-H, Fixed, 95% C1 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 0.045 Ratio (1.51, 6.21) 0.05 [0.72, 2.6] 0.05 [0.72, 1.6] 0.085 [0.70, 1.0] Odds Ratio 0.085 [0.70, 1.0] 0.045 Ratio	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (RV) positive) 1 Favours (RV) positive) 1 Favours (VPI high 0.01 0.1 Favours (VPI high 0.01 0.1 F	1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kinger K et al-1 2017 Kinger K et al-1 2017 Total (95% CI) Study or Subgroup Krüger K et al-1 2017 Lurry S et al 2008 Total (95% CI) Total eversts Heterogeneity: Ch ² = 4 Study or Subgroup Krüger K et al-2017	$ \begin{array}{c} \text{e.so} (F = 0, G $	96) Evinepaid Events 144 25 39 94%; I ² = 00 VPI I 44 112 Events 44 112 44 112 45 25 VPI I 45 45 45 45 45 45 45 45 45 45	tive trol W 158 236 394 10 394 10 339 10 % Total 133 390 4 4 0% 390 4 127 4 0% 5 5 6 6 6 10 127 390 4 127 390 4 127 128 6 6 6 6 6 6 6 6 14 10 18 1 6 221 18 18 6 221 8 2 2 5 4 10 18 6 12 10 18 6 221 12 12 13 13 10 12	weight 1 100,00% 2 100,00% 2 100,00% 2 100,00% 37,4% 100,00% 37,4% 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 3,119 100,00% 4,88 0 5,019 100,00% 100,00% Weight 2,6,8%	Ords Ratio +, Fixed, 95% C1 ≥56 [1.03, 4, 7.69] ≥56 [1.3, 5.81] ≥56 [1.3, 5.81] ≥56 [1.3, 5.81] ≥56 [1.3, 5.81] ≥60 [1.36, 4.97] → 0.045 Ratio -1.51, 5.21] 3.00 [1.91, 4, 7.1] Odds Ratio -1.54, 5.31 3.00 [1.91, 4, 7.1] Odds Ratio -0.85 [0.72, 1.6 0.85 [0.72, 1.6 0.98 [0.41, 2.3 4.0.98 [0.41, 2.3 5.0.85 [0.70, 1.0 Odds Ratio M-H, Fixed, 95% C 0.45 [0.72, 1.6 0.45 [0.72, 1.5 0.45 [0.72, 1.5] Odds Ratio	0.01 0.1 0.01 0.1 0.02 00005 [N- 0.01 0.1 Favours [N/P high 0.01 0.1 Favours [VPI high 0.01 0.1 0.01 0.1 Favours [VPI high 0.01 0.1 Favours [VPI high	1 10 100 1 Favours [N0] atio 95% Cl 10 100 100 100 100 100 100 100
E Study or Subgroup Study or Subgroup Kroger K et al-1 2017 Kroger K et al-1 2017 Kroger K et al-1 2017 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Study or Subgroup Study or Subgroup Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-2 CO1 Total (95% CI) Total (95% CI) Total 2014 Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-2018 Goo NN et al 2014 Kröger K et al-2017 Total (95% CI) Total events Total events Hort overall effect: Z D Study or Subgroup Asleh K et al-2017 Kröger K et al-12017 Total events Total events Total events Kröger K et al-12017 Kröger K et al-12017 Kröger K et al-12017 Kröger K et al-12017	$\begin{array}{c} \text{e.s} 0.05 \ (\text{F}=0. \\ \text{e.s} 0.15 \ (\text{F}=0. \\ \text{e.s} 0.15 \ \text$	96) EVInegal EVInegal EVInegal EVInegal EVInegal I EVIn	tive transmission $Total$ W 158 236 236 33 W	Veight I Veight I 21.7% 40.9% 37.4% 5.2% 21.7% 40.9% 37.4% 5.6% 8 76.2% 9 5.6% 9 5.6% 40.9% 37.4% 8 76.2% 9 5.0% 9 5.0% 9 5.0% 9 5.2% 2 2.6.% 9.8% 5.2%	Odds Ratio H, Fixed, 95% C1 2.68 (0.04, 7.69) 2.68 (0.04, 7.69) 2.68 (0.04, 7.69) 2.68 (0.04, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.51, 6.21] 3.00 [1.91, 4.71] Odds Ratio M-H, Fixed, 95% C1 0.03 [0.42, 2.0 0.03 [0.42, 2.0 0.05 [0.70, 1.0 0.45 [0.70, 1.0] 0.45 [0.70,	0.01 0.1 0.01 0.1 Odds m M-H, Fixed 0.01 0.1 Favours (VPI high 0.01	1 10 100 1 Favours [N0] atio 395% Cl 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% CI) Total (95% CI) Total (95% CI) Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% CI) Total (95% CI) <	$\begin{array}{c} 0.05 \ (r=0. \\ 0.01 \ (r=0. \ (r=0. \\ 0.01 \ (r=0. \ (r=0.$	96) 950 14 12 25 25 39 97 347 17 341 17 344 11 347 26 347 26 341 Events 344 121 344 121 344 121 342 24 341 Events 342 27 263 111 115 111 116 Events 126 11 126 24 263 11 126 11 127 11 128 11 129 11 120 11 121 11 122 11 123 11 124 12 125 11 126 11 127 11	tive transmission 158 236 158 236 236 333 $10w$ 5 $50 + 100$ 330 4 33 4 127 390 4 4 700 4 700 8	veight 1 0.0% 2 0.0% 2 0.0% 2 0.0% 2 0.0% 2 0.0% 2 0.0% 37.4% 100.0% 37.4% 100.0% 5.0% 100.0% 5.0% 100.0% 5.0% 2.5% 5.3% 2.6% 5.8% 5.3% 5.0% 5.2% 5.2% 5.2% 5.2% 6.1% 5.2% 6.1% 2.1%	Odds Ratio H, Fixed, 95% CI 2.68 (0.94, 7.69) 2.56 (1.33, 5.81) 2.56 (1.33, 5.81) 2.56 (1.33, 5.81) 2.60 (1.36, 4.97) 0.00 Odds Ratio M-H, Fixed, 95% CI 0.80 (0.63, 1.0 0.83 (0.63, 1.0 0.83 (0.63, 1.0 0.83 (0.63, 1.0 0.83 (0.63, 1.0 0.83 (0.63, 1.0 0.83 (0.72, 2.6 0.83 (0.72, 2.6 0.85 (0.73, 1.0 0.85 (0.73, 1.0 0.45 (0.73, 1.0) 0.45 (0.73, 1.0 0.45 (0.73, 1.0) 0.45 (0.74, 1.0) 0.45 (0.74	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours [BVI positive] 1 0.01 0.1 Favours [VPI high Favours [VPI high 0 0dd M-H, Fix 0 0dd M-H, Fix 0 0dd M-H, Fix 0 0dd M-H, Fix 0 0dd 0 0dd M-H, Fix 0 0dd 0 0 0dd 0 0dd 0 0dd 0	1 10 100 1 1 Favours [N0] 1 10 1
Budy or Subgroup Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% C) Total of Store Study or Subgroup Krüger K et al-1 2017 Krüger K et al-1 2017 Krüger K et al-1 2017 Total (95% C) Total events Heterogeneity: Chi² = 0.0 Fust for overall effect: 2 Study or Subgroup Arieh K et al 2018 Gao NN et al 2014 Krüger K et al-1 2017 Total events Heterogeneity: Chi² = 0. Asleh K et al 2018 Krüger K et al-1 2017	$ \begin{array}{c} \text{e.s} 0.05 \ (\text{F}=0. \text{ fr}) \\ \text{Events Total} \\ \text{Events Total} \\ \text{for } 10^{-0} \text{ or } 0^{-0} \\ \text{for } 10^{-0} or $	96) BVI negative 12 12 23 23 39 39 44 12 44 12 44 12 45 64 41 121 41 121 112 12 412 12 25 22 26 24 412 12 113 115 1115 26 26 26 27 26 43 26 26 26 27 26 49 0 28 26 27 26 43 26 28 27 28 27 28 26 28 27 28 27 28 27 29 0 20 28 <td< td=""><td>tive Total W Total 394 10 158 </td><td>Weight 1 21,7% 3,7.4% 30,00% 2 31,74% 3,7.4% 100,0% 2 31,9% 3,7.4% 100,0% 3 30 5,00,0% 4 9% 31,9% 5,00,0% 32,0% 2,6,8% 34,0% 5,00,0% Weight 1,00,0% Weight 2,6,8% 4,9,8% 5,2% 5,2% 5,2% 6,1% 6,1% 100,0% 100,0%</td><td>Odds Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.56 (1.13, 5.81) 2.56 (1.3, 5.81) 2.56 (1.3, 5.81) 2.56 (1.3, 5.81) 2.60 (1.36, 4.97) 0.00 0.0</td><td>0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours [W] positive] 1 Favours [W] positive] 1 Favours [W] high 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 d</td><td>1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10</td></td<>	tive Total W Total 394 10 158	Weight 1 21,7% 3,7.4% 30,00% 2 31,74% 3,7.4% 100,0% 2 31,9% 3,7.4% 100,0% 3 30 5,00,0% 4 9% 31,9% 5,00,0% 32,0% 2,6,8% 34,0% 5,00,0% Weight 1,00,0% Weight 2,6,8% 4,9,8% 5,2% 5,2% 5,2% 6,1% 6,1% 100,0% 100,0%	Odds Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.56 (1.13, 5.81) 2.56 (1.3, 5.81) 2.56 (1.3, 5.81) 2.56 (1.3, 5.81) 2.60 (1.36, 4.97) 0.00 0.0	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours [W] positive] 1 Favours [W] positive] 1 Favours [W] high 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 dd M-H, Fix 0 dd 0 d	1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10
B Study or Subgroup Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total (95% C) Total (95% C) Total (95% C) Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total (95% C) Total (95% C) Aleh K et al 2018 Gao NN et al 2018 Aleh K et al 2018 Gao NN et al 2018 Total (95% C) Total events Heterogeneity: Chi² = 0. Parry S et al 2018 Gao NN et al 2018 Gao NN et al 2018 Früger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12018 Total events Heterogeneity: Chi² = 0. Krüger K et al-12017 Krüger K et al-12017 Krüger K et al-12017 K	■ 0.05 (F = 0. 8 V positive Events Total 6 29 10 43 16 72 0, df - 1 (F + 0.05 V) 20, df - 1 (F + 0.05 V) 16 72 0, df - 1 (F + 0.05 V) 16 72 0, df - 1 (F + 0.05 V) 19 - 1 19 - 1 10, df = 2 (F + 0.05 V) 22 - 1 13 4 11 1 13 11 1 14 15 13 4 13 11 1 12 2 43, df = 5 (P, 0.05 V) 13 4 11 1 13 1 13 1 13 1 15 1 15 1 15 1 16 11 15 1 16 11 17 2 16 20 V + 0.05 V) 17 20 V + 0.05 V + 0.05 V 17 20 V + 0.05 V 17	960 950 Events 14 12 25 39 39 39.47; F = 00 44 11 44 11 47 25 26 37 64 44 11 47 29 64 64 41 21 90 2 41 12 91 42 90 2 42 1 90 2 72 72 72 72 72 72 72 72 72 72 72 72 72 72 73 74 74 74 72 72 73 74 74 74 74 74 74 74 74 74 74 </td <td>tive Total W 158 </td> <td>Weight I 21,7% 3,7,4% 30,0% 2 Weight 1 21,7% 40,9% 40,9% 7,4% 100,0% 2 Weight 8 5,81% 5,63% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 26,8% 5,2% 5,2% 6,1% 12,1% 100,0%</td> <td>Odds Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.03 0.03 0.02 0.02 0.03 0.02 0</td> <td>0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours (N/P high 0.01 0.1 Favours (VPI high 0.01 0.1 0.1 Favours (VPI high 0.01 0.1 Favours (LVI- 0.01 0.1 Favou</td> <td>1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100</td>	tive Total W 158	Weight I 21,7% 3,7,4% 30,0% 2 Weight 1 21,7% 40,9% 40,9% 7,4% 100,0% 2 Weight 8 5,81% 5,63% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 9 5,13% 26,8% 5,2% 5,2% 6,1% 12,1% 100,0%	Odds Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.03 0.03 0.02 0.02 0.03 0.02 0	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours (N/P high 0.01 0.1 Favours (VPI high 0.01 0.1 0.1 Favours (VPI high 0.01 0.1 Favours (LVI- 0.01 0.1 Favou	1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100
$ \begin{array}{l} \begin{array}{l} \begin{array}{l} \begin{array}{l} \begin{array}{l} \begin{array}{l} \\ \end{array} \\ \begin{array}{l} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	$\begin{array}{c} \text{e.so} (r = 0. \ \text{so} (r = 0. \ \text{so}$	960 SVI negative 144 25 39 39 39 39 341 7 364 114 44 111 47 29 36 64 37 64 64 24 37 64 121 194 121 194 121 194 122 12 131 242 141 29 2 21 115 22 115 24 12 19 2 2 1115 26 42 12 121 11 122 2 133 26 429 2 43 26 42 2 43 26 443 26 420 2	tive Total W Total 394 11 158	Weight I 21.7% 3.7.4% 30.0% 2 Weight 1 21.7% 40.9% 37.4% 100.0% 2 8 58.8 76.2% 3.14 9 5.13 9 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.14 26.8% 5.2% 5.2% 6.1% 100.0% 6.1%	O'05 Odds Ratio +, Fixed, 95% C1 ≥68 (0.04, 7.69) ≥68 (0.04, 7.69) ≥69 (0.136, 4.97) 2.60 (1.36, 4.97) 2.60 (1.36, 4.97) 2.60 (1.36, 4.97) 2.63 (1.09, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio 1.04 (0.63, 1.04) 4.038 (0.63, 1.04) 4.038 (0.63, 1.04) 4.038 (0.63, 1.04) 4.038 (0.63, 1.04) 4.038 (0.63, 1.04) 5.048 (0.63, 1.04) 0.045 (0.72, 2.04) 5.048 (0.72, 2.04) 0.048 (0.72, 2.04) 5.048 (0.72, 2.04) 5.048 (0.72, 2.04) 5.048 (0.72, 2.04) 5.048 (0.72, 2.04) 0.045 (0.72, 2.04) 5.048 (0.74, 2.04) 5.048 (0.748, 0.748) 5.048 (0.748, 0.748) 5.048 (0.748, 0.748) 5.048 (0.748, 0.748) 5	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1	1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100
Budy or Subgroup Study or Subgroup Kröger K et al-1 2017 Kröger K et al-1 2017 Kröger K et al-1 2017 Total (95% CI) Total (95% CI) Total (95% CI) Kröger K et al-1 2017 Kröger K et al-2018 Gao NN et al 2014 Kröger K et al-2012 Sudy or Subgroup Asleh K et al 2014 Kröger K et al-2017 Kröger K et al-2018 Gao NN et al 2014 Kröger K et al-2017 Kröger K et al-2018 Total events Heterogeneity: Chi ² = 4 Kröger K et al-2017 Kröger K e	$ \begin{array}{c} \text{e} 0.05 \ (\text{F}=0. \text{ fr}) \\ \text{Events Total} \\ \text{Events Total} \\ \text{f} 0 \\ $	96) Events: 125 25 39 94); f = 0 VPI pl 44 41 44 41 42 42 42 42 42 42 42 42 42 42	tive w Total W 158	Veight Weight 21.7% 37.4% 30.0% 2 Weight 100.0% 21.7% 37.4% 100.0% 2 Weight 8 5.313 37.4% 100.0% 3.18 9 5.13 9 5.34 9 5.03 9 5.03 9 5.03 9 5.03 100.0% 100.0%	O'95 Odds Ratio +, Fixed, 95% C1 ≥56 [1.03, 4, 7.69] ≥56 [1.03, 4, 7.69] ≥56 [1.03, 4, 7.69] ↓000 Odds Ratio 	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (IVP lositive) 1 Favours (IVP lositive) 1 0.01 0.1 Favours (IVP lositive) 1 0.00 0.1 Favours (IVP lositive) 1 0.00 0.1 Favours (IVP lositive) 1 Favours (IVP los	1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10
Best Study or Subgroup Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Study or Subgroup Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Total (95% CI) Total (95% CI) Total events Heterogeneity: Chi ² = 0. Asleh K et al 2014 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017 Krüger K et al1 2017		96) Events: 12 25 39 94); (1 = 00 VPIP 44 41 44 41 44 41 42 42 44 42 44 42 44 42 42 44 42 42	tive trive trive Total W 158 158 394 10 % Total 133 9 130 133 9 130 14 133 9 130 4 127 390 4 127 390 4 0 18 66 66 66 9 6 66 221 54 33 0 2 54 4 33 1 0 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 1 2 54 <td>Weight Weight 100.0% 2 21.7% 4.9% 4.9% 5.7.4% 100.0% 2 Weight 100.0% Weight 2.1.1% 4.9% 5.13 8 7.6.2% 9.5 5.13 8 4.8% 0 5.00 5.2% 6.1% 2.2.8% 6.1% 100.0% Weight 100.0% Weight</td> <td>Ords Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.85 (1.03, 7.43] 3.00 (1.91, 4.631] 3.00 (1.91, 4.71] Odds Ratio M-H, Fixed, 95% C1 0.03 (104, 2.0 0.03 (109, 2.0 0.03 (104, 2.0 0.00 (104, 2.0) (104, 2.0 0.00 (104, 2.0) (104, 2.</td> <td>0.01 0.1 0.01 0.1 Odds m M-H, Fixed 0.1 - Favours (IVP heigh 0.01 0.1 Favours (VPI height) 0.002 0.1 Favours</td> <td>1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10</td>	Weight Weight 100.0% 2 21.7% 4.9% 4.9% 5.7.4% 100.0% 2 Weight 100.0% Weight 2.1.1% 4.9% 5.13 8 7.6.2% 9.5 5.13 8 4.8% 0 5.00 5.2% 6.1% 2.2.8% 6.1% 100.0% Weight 100.0% Weight	Ords Ratio H, Fixed, 95% C1 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 2.68 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.85 (1.03, 7.43] 3.00 (1.91, 4.631] 3.00 (1.91, 4.71] Odds Ratio M-H, Fixed, 95% C1 0.03 (104, 2.0 0.03 (109, 2.0 0.03 (104, 2.0 0.00 (104, 2.0) (104, 2.0 0.00 (104, 2.0) (104, 2.	0.01 0.1 0.01 0.1 Odds m M-H, Fixed 0.1 - Favours (IVP heigh 0.01 0.1 Favours (VPI height) 0.002 0.1 Favours	1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10
B Study or Subgroup Study or Subgroup Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Total (95% C) Total (95% C) Total (95% C) Study or Subgroup Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Kringer K et al-12017 Total (95% C) Total (95% CI) Total (95% CI)		96) 950 12 12 12 25 39 9 14 12 15 24 16 24 17 29 24 24 24 24 25 64 26 24 27 29 28 11 12 12 28 1 29 2 29 2 21 12 42 12 282 12 282 12 282 11 111 12 12 14 143 15 111 14 12 12 143 14 15 1 16 1 17 10 18 1 19 1 10	tive W W Total 158 1 158 158 3 3994 10 3 % 3900 3 = 0% 3900 3 = 0% 6 168 = 0% 6 164 10 6 6 2 54 1 0 15 1 0 35 1 2 54 35 0 15 1 0 35 1 10 35 1 2 54 35 0 15 1 1 26 34 1 26 35 1 26 35 1 26 35 1 26 35 2 54 52	Weight M 36 8% 2 36 8% 2 36 8% 2 36 8% 2 36 7 3 100.0% 2 100.0% 2 21,7% 40.9% 37,4% 100.0% 100.0% 2 26,8% 3.13 26,8% 3.2% 12,1% 100.0% Weight 1 26,8% 100.0% Weight 1 26,8% 64,5%	Odds Ratio H, Fixed, 95% CI 2.65 (0.04, 7.69) 2.65 (0.04, 7.69) 2.65 (0.04, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% CI 2.65 (1.09, 7.43) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio M-H, Fixed, 95% CI 0.63 (0.72, 2.6 0.63 (0.72, 2.6) 2.53 (1.21, 5.26 0.64 Ratio M-H, Fixed, 95% CI 1.02 (0.72, 3.81) 1.39 (0.62, 3.12)	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours [W] positive] 1 Favours [W] positive] 1 0.01 0.1 Favours [W] high 0.01 0.1 Favours [W] high 0.01 0.1 Favours [VP] high 0.01	1 10 100 1 1 2000 100 2000 100 100 2000 100 100 2000 100 100 2000 100 100 2000 1
e Sudy or Subgroup Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total vents Heterogeneity: Ch ² = 0.0 Test for overall effect: Z = f Study or Subgroup Krüger K et al-12017 Krüger K et al-12017 Total (95% C) Total vents Heterogeneity: Ch ² = 0.0 Test for overall effect: Z g Study or Subgroup Study or Subgroup Asleh K et al 2018 Gao NN et al 2014 Krüger K et al-12017 Krüger K et al-12017 Ku get K et al-12012 Liu C G et al 2012 Zhu J et al 2009	$\begin{array}{c} \text{e.s} 0.05 \ (\text{F}=0. \\ \text{Events} \text{Total} \\ \text{Events} \text{Total} \\ \text{e.s} 0 \ (\text{f}=0. \\ \text{f}=0. \\ \text{f}=0. \ (\text{f}=0. \ (\text{f}=0. \\ \text{f}=0. \ (\text{f}=0. \ (\text$	960 950 14 12 25 25 39 39 44 12 44 12 44 12 44 12 44 12 41 12 42 14 41 12 42 12 41 12 9 6 64 24 112 19 113 12 114 24 2 2 2.82 2 2.6 2 2.6 2 2.6 2 1115 12 12 26 43 2 2.6 2 2.8 2 1.3 3 12 2.6 43 2 2.6 2 2.7 2.7 3.8	tive W Total W 156 133 394 10 \sim 133 \sim 133 \sim 133 \sim 133 \sim 133 \sim 133 \sim 127 $=$ 0% egative ts total 18 $=$ 0% 2 54 0 15 1 26 \sim 7 $=$ 0% S Total 19 52 11 11	Veight M 36.8% 2 36.2% 2 36.2% 2 36.2% 2 37.4% 37.4% 100.0% 2 40.9% 8 37.4% 37.4% 100.0% 2 40.9% 8 5.2% 3.1% 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.13 9 5.20 9.0% 5.20	Odds Ratio H, Fixed, 95% C1 2.65 (0.94, 7.69) 2.65 (0.94, 7.69) 2.65 (0.94, 7.69) 2.65 (0.94, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 0.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 3.00 (1.51, 6.21) 0.03 (0.63, 1.0 0.03 (0.63, 1.0 0.03 (0.63, 1.0 0.05 (0.63, 1.0 0.05 (0.63, 1.0 0.05 (0.70, 1.0) 0.045 Ratio M-H, Fixed, 95% C1 1.02 (0.27, 3.81) 3.29 (0.14, 6.082 3.32 (0.42, 2.6.30 2.53 (1.21, 5.26 0.045 Ratio M-H, Fixed, 95% C1 1.02 (0.27, 3.81) 1.39 (0.62, 3.12) 2.11 (0.25, 3.749)	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.1 Favours [VV] positive] 1 Favours [VV] high 0.01 0.1 Favours [VV] high 0.01 0.1 Fav	1 10 100 1 Favours [N0] 10 10 10 10 10 10 10 10 10 10
Bit State State of State State State of State State State State State State State State State State State State State State State <td>$\begin{array}{c} \text{e-constraints}\\ \text{Events} & \text{Total}\\ \text{Events} & \text{Total}\\ \text{e-constraints}\\ e-constraints$</td> <td>960 950 EVIntegal 14 25 39 39 39 39 39 39 39 44 121 45 24 46 24 47 76 44 121 41 21 41 21 90 2 42 12 90 2 42 12 90 2 42 12 90 2 42 12 90 2 42 12 90 2 82 26 42 1 12 12 90 2 8 3 9 1 9 2 9 2 9 2 9 1 9 1</td> <td>tive ut Total 156 133 133 3994 10 s Total 133 133 14 127 3904 127 3904 127 s Total 10 133 s Total s Total s Total s 133 s Total s 19 s 133 s Total s 113 s Total s 11 s 133 s 133 <math>r 0% s 133 <math>r 0% s 133 <math>r 133 <math>r 133 <math>r 133 <math>r 133 <math>r 132 r</math></math></math></math></math></math></math></td> <td>Weight Meight 1 21,7% 40,9% 36,8% 7,4% 100,0% 2 Weight 1 8 100,0% 37,4% 100,0% 8 100,0% 8 Weight 1 8 20,0% 2 20,0% 2 30 5,0% 4,8% 5,2% 20,6% 6,1% 12,1% 100,0% Weight 1 0,5% 44,5% 9,0% 100,0% 100,0%</td> <td>Odds Ratio H, Fixed, 95% C1 2.65 (0.04, 7.69) 2.66 (0.04, 7.69) 2.66 (0.04, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.65 (1.05, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio (M-H, Fixed, 95% C1 0.65 (0.72, 2.6 0.68 (0.63, 1.0 0.63 (0.72, 2.6 0.69 (0.72, 3.15, 5 0.65 (0.70, 1.0 Odds Ratio M-H, Fixed, 95% C1 1.02 (0.27, 3.81) 3.29 (0.16, 6.082 3.32 (0.42, 2.63) 2.53 (1.21, 5.26 Odds Ratio 1.92 (0.27, 3.61) 1.39 (0.62, 3.12] 2.11 (0.25, 17.49) 1.36 (0.70, 2.6.1]</td> <td>0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (IV) positive) 1 Favours (IV) positive) 1 Favours (IVP high 0.01 0.1 Favours (IVP high 0.00 0.1 F</td> <td>1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100</td>	$\begin{array}{c} \text{e-constraints}\\ \text{Events} & \text{Total}\\ \text{Events} & \text{Total}\\ \text{e-constraints}\\ e-constraints$	960 950 EVIntegal 14 25 39 39 39 39 39 39 39 44 121 45 24 46 24 47 76 44 121 41 21 41 21 90 2 42 12 90 2 42 12 90 2 42 12 90 2 42 12 90 2 42 12 90 2 82 26 42 1 12 12 90 2 8 3 9 1 9 2 9 2 9 2 9 1 9 1	tive ut Total 156 133 133 3994 10 s Total 133 133 14 127 3904 127 3904 127 s Total 10 133 s Total s Total s Total s 133 s Total s 19 s 133 s Total s 113 s Total s 11 s 133 s 133 $r 0% s 133 r 0% s 133 r 133 r 133 r 133 r 133 r 132 r$	Weight Meight 1 21,7% 40,9% 36,8% 7,4% 100,0% 2 Weight 1 8 100,0% 37,4% 100,0% 8 100,0% 8 Weight 1 8 20,0% 2 20,0% 2 30 5,0% 4,8% 5,2% 20,6% 6,1% 12,1% 100,0% Weight 1 0,5% 44,5% 9,0% 100,0% 100,0%	Odds Ratio H, Fixed, 95% C1 2.65 (0.04, 7.69) 2.66 (0.04, 7.69) 2.66 (0.04, 7.69) 0.00 Odds Ratio M-H, Fixed, 95% C1 2.65 (1.05, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio (M-H, Fixed, 95% C1 0.65 (0.72, 2.6 0.68 (0.63, 1.0 0.63 (0.72, 2.6 0.69 (0.72, 3.15, 5 0.65 (0.70, 1.0 Odds Ratio M-H, Fixed, 95% C1 1.02 (0.27, 3.81) 3.29 (0.16, 6.082 3.32 (0.42, 2.63) 2.53 (1.21, 5.26 Odds Ratio 1.92 (0.27, 3.61) 1.39 (0.62, 3.12] 2.11 (0.25, 17.49) 1.36 (0.70, 2.6.1]	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (IV) positive) 1 Favours (IV) positive) 1 Favours (IVP high 0.01 0.1 Favours (IVP high 0.00 0.1 F	1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100
B Study or Subgroup Study or Subgroup Kriger K et al-1 2017 Kriger K et al-1 2017 Kriger K et al-1 2017 Total (95% CI) Total (95% CI) Total or Subgroup Kriger K et al-1 2017 Kriger K et al-1 2017 Kriger K et al-1 2017 Kriger K et al-1 2017 Kriger K et al-1 2017 Kriger K et al-1 2017 Total (95% CI) Total (95% CI) Total (95% CI)	$ \begin{array}{c} \text{e.so} (r = 0, \text{ fr} = 0, \text{ fr}$	96) Events: 125 25 39,40; r 00 940; r	tive twill Total 156 158 394 s Total 133 133 s Total s Total s 133 s 133 s 100 s Total s 0	Weight Weight 100.0% 2 weight 10 36.8% 7.4% 100.0% 2 weight 10 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2 100.0% 2	O'95 Odds Ratio +, Fixed, 95% C1 ≥68 (0.34, 7.69) ≥68 (0.34, 7.69) ≥68 (0.34, 7.69) ≥60 (1.36, 4.97) 2.60 (1.36, 4.97) 2.60 (1.36, 4.97) 2.63 (1.09, 7.43) 3.06 (1.51, 6.21) 3.00 (1.91, 4.71) Odds Ratio (1.91, 4.71) Odds Ratio (1.91, 4.71) Odds Ratio 0.83 (0.63, 1.0 (2.93, 1.05, 9, 1.07, 1.0 Odds Ratio 0.48 (0.72, 2.6, 1.05, 9, 1.07, 1.0 Odds Ratio 0.48 (0.72, 2.6, 1.05, 9, 1.07, 1.0 Odds Ratio 0.41, 6, 63, 2.3 3.29 (0.18, 60, 82, 3.2 3.29 (0.18, 60, 82, 3.2) 3.29 (0.18, 60, 82, 3.2) 3.29 (0.18, 60, 82, 3.2) 2.53 (1.21, 5.26 Odds Ratio 4.44, Fixed, 95% C1 1.10 (0.27, 3.81) 1.39 (0.62, 3.12) 1.39 (0.	0.01 0.1 0.01 0.1 Odds B M-H, Fixed 0.01 0.1 Favours (IVP positive) 1 Favours (IVP positive) 1 Favours (IVP high 0.01 0.1 Favours (IVP high 0.01 0.1 0.01 0.1 0.002 0.1 Favours (LVI 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1 0.002 0.1	1 10 100 1 Favours [N0] atio 95% C1 10 100 100 100 100 100 100 100

Fig. 3 Forest plots of the correlation between nestin expression and clinicopathological parameters. **a** Age (age > 35 vs. age < 35); **b** TNM stage (grade III vs. grade I–II); **c** Tumor size (T_{2–4} vs. T₁); **d** Lymph node metastasis (N₊ vs. N₀); **e** BVI (positive vs. negative); **f** VPI (high vs. low); **g** LVI (positive vs. negative); **h** IDC vs. ILC; **i** IDC vs. DCIS

Fig. 4 Forest plots of the correlation between nestin expression and IHC markers. **a** ER (positive vs. negative); **b** PR (positive vs. negative); **c** HER2 (positive vs. negative); **d** Ki-67 (high vs. low); **e** TNBC vs. Non-TNBC; **f** CK5 (positive vs. negative); **g** P-cadherin (positive vs. negative); **h** EGFR (positive vs. negative); **i** BLP1 (present vs. absent); **j** BLP2 (present vs. absent); **k** BLP3 (present vs. absent); **l** BLP4 (present vs. absent); **m** BLP5 (present vs. absent); **n** p53 (positive vs. negative); **o** FOXA1 (positive vs. negative)

(positive vs. negative, pooled OR=0.85, 95% CI [0.70, 1.04], P=0.11, $I^2=0\%$) (Fig. 3g).

Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common histological types of invasive breast cancer (IBC) [57]. Five datasets from two studies [24, 27] investigated the differential expression of nestin between IDC and ILC. Pooled result revealed an increased expression level of nestin in IDC when compared with ILC (pooled OR=2.53, 95% CI [1.21, 5.26], P=0.01, I²=0%) (Fig. 3h). Moreover, three studies [25, 26, 56] were included in the comparison of nestin expression between IDC and ductal carcinoma in situ (DCIS). It revealed that there was no significant difference in nestin expression between IDC and DCIS (IDC vs. DCIS, pooled OR=1.36, 95% CI [0.70, 2.61], P=0.36, I²=0%) (Fig. 3i).

Correlation between nestin expression and immunohistochemical markers

A total of 11 datasets from 8 studies [21-24, 26-28, 56] investigated the correlation of nestin expression with the expression of ER, PR, HER-2 and Ki-67. The pooled results showed that nestin expression was negatively associated with the expression of ER (pooled OR = 0.12, 95% CI [0.08, 0.19], P<0.00001, $I^2 = 70\%$) (Fig. 4a) and PR (pooled OR=0.19, 95% CI [0.12, 0.30], P<0.00001, $I^2 = 57\%$) (Fig. 4b). Besides, nestin expression was positively correlated with high expression of cell proliferation marker Ki-67 (pooled OR=6.00, 95% CI [3.28, 10.96], P < 0.00001, $I^2 = 81\%$) (Fig. 4d). However, there was no significant association between the expression of nestin and HER-2 status (pooled OR = 0.71, 95% CI [0.44, 1.15], P = 0.17, $I^2 = 51\%$) (Fig. 4c). More importantly, nine studies with 4335 patients [21-23, 25-28, 55, 56] compared the nestin expression between triple negative breast cancer (TNBC) and non-triple negative breast cancer. With moderate heterogeneity (P=0.007, $I^2=62\%$), the pooled analysis in random-effects model revealed nestin was preferentially expressed in TNBC than that in non-TNBC (pooled OR = 9.34, 95% CI [5.92, 14.73], P<0.00001) (Fig. 4e). Additionally, the correlation between the expression nestin and some other biomarkers, such as p53 and forkhead box protein A1 (FOXA1), was also reported in several studies [22, 24, 26, 27]. Nestin



а	Yes		No			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
1.1.1 Chemotherapy							
Asleh K et al 2018	124	897	246	2729	97.8%	1.62 [1.29, 2.04]	
Tampaki EC et al 2017	23	104	2	34	2.2%	4.54 [1.01, 20.40]	
Subtotal (95% CI)		1001		2763	100.0%	1.68 [1.34, 2.11]	•
Total events	147		248	0.01012			
Heterogeneity: $Chi^2 = 1.7$	79, df =	1 (P = 0)).18); l² ⊧	= 44%			
Test for overall effect: Z	= 4.51 (P	<i><</i> 0.0	0001)				
D 1.1.2 Hormonal therapy							
Asleh K et al 2018	75	1441	295	2185	100.0%	0.35 [0.27, 0.46]	
Subtotal (95% CI)		1441		2185	100.0%	0.35 [0.27, 0.46]	
Total events	75		295				
Heterogeneity: Not applie	cable						
Test for overall effect: Z	= 7.79 (P	< 0.0	0001)				
С							
1.1.3 Radiotherapy							
Tampaki EC et al 2017	18	81	7	57	100.0%	2.04 [0.79, 5.27]	
Subtotal (95% CI)		81	_	57	100.0%	2.04 [0.79, 5.27]	
Total events	18		7				
Heterogeneity: Not applie	cable	1	~				
Test for overall effect: Z	= 1.47 (P	y = 0.1	4)				
							0.05 0.2 1 5 20
Test for subgroup differe	ences: Ch	$i^2 = 81$.37. df =	= 2 (P <	0.00001), $l^2 = 97.5\%$	Favours [Yes] Favours [No]
Fig 5 Forest plots of the co	rrelation	hotwork	n nostin		ion and a	diuvant systemic thoras	nies a Chemotherapy: b Hormonal therapy: c
Radiotherapy	neiation	Dermee	en nestin i	expless	1011 al 10 al	ajuvani systemic therap	nes, a chemotherapy, b normonal therapy, C

expression revealed significant association with positive p53 nuclear expression (pooled OR=4.34, 95% CI [2.99, 6.29], P < 0.00001, I^2 =30%) (Fig. 4n) and negative expression of FOXA1 (pooled OR=0.12, 95% CI [0.02, 0.61], P=0.01, I^2 =71%) (Fig. 4o).

Three studies with six datasets [21, 24, 27] were included in the analysis of the association of nestin expression with basal-like markers cytokeratin 5 (CK5), P-cadherin and epidermal growth factor receptor (EGFR). The pooled results demonstrated that nestin expression was significantly correlated with the positive expression of CK5 (pooled OR=7.96, 95% CI [6.32, 10.04], P<0.00001, I²=0%) (Fig. 4f), P-cadherin (pooled OR=7.80, 95% CI [5.42, 11.22], P<0.00001, $I^2 = 0\%$) (Fig. 4g), and EGFR (pooled OR = 6.61, 95% CI $[5.25, 8.32], P < 0.00001, I^2 = 48\%$ (Fig. 4h). Moreover, four series (series I-IV) from the study by Krüger et al. [24] with 1172 breast cancer patients also investigated the correlation of nestin expression with basal-like profiles (BLP). As Krüger et al. [24] described, five basal-like profiles (BLPs) were defined based on the combination of different IHC markers (BLP1: ER⁻, HER2⁻, CK5+; BLP2: ER⁻, HER2⁻, P-cadherin+; BLP3: ER⁻, HER2⁻, EGFR+; BLP4: ER⁻, HER2⁻, CK5+ and/or EGFR+; BLP5: ER⁻, HER2⁻, CK5+ and/or P-cadherin+ and/or EGFR+). Among these five BLPs, BLP4 is regarded as a core basal phenotype (CBP). The pooled results revealed that nestin expression was strongly correlated with the presence of BLPs (BLP1: pooled OR=21.28, 95% CI [13.13, 34.47], P<0.00001, I²=0%; BLP2: pooled OR=17.86, 95% CI [11.72, 27.21], P<0.00001, I²=24%; BLP3: pooled OR=12.78, 95% CI [6.69, 24.41], P<0.00001, I²=0%; BLP4: pooled OR=20.84, 95% CI [11.99, 36.22], P<0.00001, I²=0%; BLP5: pooled OR=24.03, 95% CI [14.08, 41.02], P<0.00001, I²=0%) (Fig. 4i-m). Furthermore, the study by Asleh et al. including 3128 patients [21] indicated that nestin was predominantly expressed in core basal subtype than that in non-core basal subtype (OR=10.59, 95% CI [8.08, 13.88], P<0.00001).

Correlation between nestin expression and adjuvant systemic therapies

Two studies [21, 55] with 3764 patients investigated the correlation between nestin expression and chemotherapy. Pooled result indicated an increased expression level of nestin in patients treated with chemotherapy than that in patients without receiving chemotherapy (pooled OR=1.68, 95% CI [1.34, 2.11], P<0.00001, $I^2=44\%$) (Fig. 5a). Besides, the study by Asleh et al. [21] also revealed that expression level of nestin was down-regulated in patients treated with hormonal therapy (Tamoxifen) than that in patients without receiving hormonal therapy (OR=0.35, 95% CI [0.27, 0.46], P<0.00001) (Fig. 5b). However, the study by Tampaki



et al. [55] showed no significant difference in nestin expression between patients with radiotherapy than that in patients without receiving radiotherapy (OR=2.04, 95% CI [0.79, 5.27], P=0.14) (Fig. 5c).

Sensitivity analysis and publication bias

Sensitivity analysis was performed to validate the stability of the pooled studies (Fig. 6, Additional file 1: Fig. S1). As shown in Table 2, no individual study could statistically significantly alter the combined results of survival outcomes and clinicopathological parameters but the study by Asleh et al. [52], the study by Liu et al. [25] and Series II from the study by Krüger et al. [24], which altered the pooled results of the correlation of nestin expression with OS (multivariate analysis), age, and LVI, respectively (Fig. 6a–c). Besides, Series III from the study by Krüger et al. [24] can affect the pooled OR of nestin expression between IDCs and ILCs (Fig. 6d). More eligible studies should be added in these pooled analyses to draw stable conclusions.

Potential publication bias of survival outcomes and clinicopathological parameters was evaluated using Begg's test (Fig. 7a-c, Additional file 2: Fig. S2) and Egger's test (Fig. 7d-f, Additional file 3: Fig. S3). As shown in Table 2, P values assessed by Begg's test and Egger's test were all greater than 0.05 except the evidence of significant publication bias (P < 0.05) in three pooled studies (Fig. 7). Therefore, the trim and fill method was utilized to evaluate the potential impacts of publication bias. For the pooled analysis of the association of nestin expression with OS of breast cancer (univariate analysis, Egger's test, P = 0.018), a filled funnel plot was generated by trim and fill analysis including two imputed studies, and the meta-analysis incorporating these two imputed studies demonstrated the similar result (univariate analysis, adjusted HR = 1.575, 95%CI [1.089–2.279], P = 0.016) (Fig. 8a). Similarly, trim and fill analysis including three imputed studies generated a symmetrical funnel plot for the pooled analysis

Table 2 Sensitivity analysis and publication bias

	Sensitivity analysis		Publication bias (P value)		
	HR/OR fluctuation	95% CI fluctuation	Begg's test	Egger's test	
Nestin expression and survival outcomes	3				
BCSS(U)	2.061-2.488	1.741-3.357	0.060	0.065	
BCSS(M)	1.240-2.000	1.000-3.810	1.000	-	
OS(U)	1.648-2.117	1.202-3.386	0.260	0.018	
OS(M)	1.715-2.362	0.862-6.474	1.000	0.536	
DMFS(U)	1.040-1.993	0.674-3.564	1.000	-	
RFS(U)	2.575-2.640	1.150-6.061	1.000	-	
Nestin expression and clinicopathologica	al parameters				
Age (> 35 vs. < 35)	0.375-0.809	0.200-2.529	1.000	0.437	
TNM stage (III vs. I-II)	4.051-5.924	2.337-10.828	0.876	0.386	
T stage $(T_{2-4} vs. T_1)$	1.256-1.568	1.046-2.097	0.917	0.340	
N stage (N_+ vs. N_0)	0.893-1.114	0.637-1.586	0.755	0.358	
IDC vs. DCIS	1.280-1.477	0.428-3.928	1.000	0.817	
IDC vs. ILC	1.927-3.935	0.890-10.835	0.221	0.056	
LVI (positive vs. negative)	0.806-1.021	0.656-1.505	1.000	0.484	
BVI (positive vs. negative)	2.558-2.683	0.936-7.689	1.000	-	
VPI (high vs. low)	2.958-3.043	1.650-5.302	0.296	0.066	
Nestin expression and immunohistocher	mical markers				
ER (positive vs. negative)	0.107-0.134	0.064-0.208	0.243	0.306	
PR (positive vs. negative)	0.167-0.218	0.105-0.341	0.474	0.455	
HER2 (positive vs. negative)	0.610-0.826	0.321-1.268	0.013	0.068	
Ki-67 (high vs. low)	4.998-7.542	2.807-14.262	0.462	0.059	
TNBC vs. Non-TNBC	7.898-10.775	5.246-18.386	0.348	0.657	
CK5 (positive vs. negative)	7.605–9.786	5.983-14.333	0.462	0.023	
P-cadherin (positive vs. negative)	7.440-8.244	4.945-12.964	0.308	0.123	
EGFR (positive vs. negative)	6.306-7.034	3.962-10.244	1.000	0.888	
BLP1 (present vs. absent)	19.543-23.784	11.296-41.447	1.000	0.629	
BLP2 (present vs. absent)	15.339-20.293	9.432-33.109	0.308	0.280	
BLP3 (present vs. absent)	12.265-13.134	4.821-31.205	0.296	0.253	
BLP4 (present vs. absent)	19.715-23.878	9.672-48.403	0.296	0.468	
BLP5 (present vs. absent)	22.230-26.590	11.294-53.144	1.000	0.683	
p53 (positive vs. negative)	3.906-5.397	2.619-8.421	0.221	0.055	
FOXA1 (positive vs. negative)	0.043-0.241	0.009–0.593	1.000	_	

of the association between the expression of nestin and CK5 (Egger's test, P=0.023), and the meta-analysis incorporating these three imputed studies demonstrated the semblable result (adjusted OR=7.091, 95% CI [5.777-8.704], P<0.001) (Fig. 8b). Despite a significant publication bias in the analysis of the association between nestin expression and HER2 status (Begg's test, P=0.013), trim and fill analysis revealed that no trimming was performed and thus pooled data remained unchanged. In conclusion, the results of the three pooled studies were robust in spite of significant publication bias.

Discussion

Nestin, initially identified as a neural stem cell marker, has recently been implicated as a positive regulator of proliferation, survival, and invasiveness of breast CSCs via the Wnt/ β -catenin pathway [20, 58]. Upregulated expression of nestin promoted the tumorigenicity of breast CSCs, whereas inhibition of nestin expression can significantly induce CSC cycle arrest at G2/M phases and promote CSC apoptosis [20]. Silencing nestin expression can notably suppress the epithelial-mesenchymal transition (EMT) process that is closely related to the invasiveness of breast CSCs [20, 26, 59, 60]. Therefore, it is





imperative to elucidate the clinical implication of nestin in breast cancer patients.

Previous studies investigated the potential prognostic and clinicopathological association of nestin expression with breast cancer patients. However, the eligible studies included in this meta-analysis were diversified and their results were contradictory. We first conducted the present meta-analysis to systematically analyze the prognostic impact of nestin expression on breast cancer patients. Pooled results demonstrated that positive expression of nestin predicted shorter BCSS and reduced OS of breast cancer patients in both univariate and multivariate analyses. Therefore, nestin is an independent factor for worse BCSS and OS of breast cancer patients. Besides, nestin-positive expression was also associated with RFS in univariate analysis, but not with DMFS based on univariate data. Of note, because only limited studies were available for the pooled analyses of the prognostic impact of nestin expression on DMFS and RFS, it was highly possible to draw unreliable and biased conclusions. Therefore, more studies to investigate the relationship between nestin expression and survival outcomes of breast cancer patients are warranted.

We then evaluated the correlation between nestin expression and clinicopathological characteristics of breast cancer patients in this meta-analysis. Nestin positivity was closely associated with earlier age for the onset of disease, higher histological grade, larger tumor size, and IDC, but not with lymph node metastasis. Nestin expression was correlated with ER negativity, PR negativity, high Ki-67 index, and positive p53 nuclear expression, but not with HER-2 status. In addition, positive expression of nestin was strongly correlated with three basal markers (CK5, P-cadherin, and EGFR) and five basal-like profiles (BLP1–BLP5). More importantly, nestin was predominantly expressed in malignant breast cancer, especially in TNBC and basal-like phenotype. Nestin expression was also revealed to be predominant in patients treated with chemotherapy and be downregulated in patients receiving hormonal therapy. These results are in accordance with the negative correlation of nestin expression with hormonal receptor expression. In view of results mentioned above, nestin expression was correlated with unfavorable clinicopathological features in breast cancer patients. Enhanced expression of nestin is a promising indicator for the malignancy of breast cancer. Of note, although Li et al. [32] evaluated nestin as a selective marker of basal epithelial breast tumors, it was reported that high levels of nestin expression were also detected in non-TNBCs and non-core basal subtypes, such as in a small group of luminal subtypes according to some studies [21-23, 25-28, 55, 56]. As a result, nestin is not actually an optimized predictor of TNBC or basallike phenotype.

Tumor angiogenesis on the basis of new vascular network formation plays a vital role in the progression and invasiveness of breast cancer [61, 62]. Apart from participation in the angiogenesis of wound healing and tissue repair in various normal tissues, nestin expression has also been implicated in tumor angiogenesis [31, 63]. Nestin-positive breast cancer stem/progenitor cells can differentiate into endothelial cells which would participate in tumor growth and vascularization [64]. Accumulated evidence suggested that nestin expression in the blood vessels is basically localized to the newly formed endothelial cell of tumor vessels [65, 66]. In this meta-analysis, we validated that nestin expression was significantly associated with positive blood vessel invasion and high vascular proliferation index in BC, but not with lymph vessel invasion. Besides, according to the study by Nowak et al. [50], increased nestin-positive microvessel density (Nestin⁺MVD) was found to be significantly associated with a shorter OS, earlier relapse, higher histological grade, and TNBCs. In consequence, nestin can be a potential angiogenesis-specific marker in BC.

Several studies also assessed the potential diagnostic and prognostic value of co-expression of nestin and some other biomarkers in breast cancer. Asleh et al. [52, 67] revealed that IHC detection of nestin and inositol polyphosphate-4-phosphatase (INPP4b) as an optimized panel of markers can be a more specific indicator for the basal-like subtype of BC regardless of ER status. Nestin positivity or loss of INPP4b (Nestin⁺ or INPP4b⁻) is an independent prognostic for BCSS of basal-like cases with weak ER positivity [67]. Liu et al. [25] found that co-expression of nestin and octamer-binding transcription factor 4 (Oct-4) was an independent prognostic factor for breast cancer (OR = 10.114, 95% CI [1.632, 62.699], P=0.013). Nestin/Oct-4 co-expression was significantly correlated with poor prognosis, younger age, lymph node metastasis, and TNBCs [25]. Besides, a study by Rögelsperger et al. [68] demonstrated that abundant expression of G-protein-coupled receptor for melatonin (MT1) was frequently observed in advanced breast cancer specimens. Previous studies showed that MT1 activation by melatonin can induce anti-tumor effects and inhibit the cell growth and metastasis of breast cancer [69, 70]. However, a high level of MT1 expression was also detected in breast cancer cells and was involved in tumor initiation and progression of breast cancer on basis of its activation independent of melatonin [71, 72]. Co-localization of nestin and MT1 in invasive breast cancer was associated with worse prognosis and advanced histological stage [68]. As a consequence, IHC detection of co-expression of nestin and relevant biomarkers provides a novel approach to more precisely predicting the prognosis of breast cancer.

There were some potential limitations to this metaanalysis. First, partial survival data were extracted from Kaplan–Meier curves in some studies, which are less dependable than data directly obtained from articles. Second, the criterion of positive nestin expression was verified among eligible studies, which may result in the heterogeneity of studies. Finally, only limited studies were included into the multivariate analysis of the correlation between nestin expression and survival outcomes, which may draw biased conclusions. This warrants further studies added into the meta-analysis of the prognostic impact of nestin expression on survival outcomes to obtain robust and reliable results. Despite the limitations mentioned above, the present meta-analysis still revealed the prognostic value of nestin expression in breast cancer patients.

Conclusions

In summary, this meta-analysis revealed the prognostic value and clinicopathological significance of nestin expression in breast cancer. Nestin is an independent prognostic factor for worse BCSS and OS of breast cancer patients. Besides, nestin is also a valuable biomarker for unfavorable clinicopathological features and tumor angiogenesis of breast cancer. More prospective studies with multivariate analysis to evaluate nestin as a therapeutic target for malignant breast cancer, especially for TNBC and basal-like phenotype, are warranted.

Supplementary information

Supplementary information accompanies this paper at https://doi. org/10.1186/s12935-020-01252-5.

Additional file 1: Table S1. Newcastle–Ottawa Scale for assessing the quality of studies in quantitative analysis.

Additional file 2: Fig. S1. Sensitivity analysis. (1) BCSS (univariate analysis); (2) BCSS (multivariate analysis); (3) OS (univariate analysis); (4) OS (multivariate analysis); (5) DMFS (univariate analysis); (6) RFS (univariate analysis); (7) TNM stage (grade III vs. grade I–II); (8) Tumor size $(T_{2-4} vs. T_1)$; (9) Lymph node metastasis (N₊ vs. N₀); (10) IDC vs. DCIS; (11) BVI (positive vs. negative); (12) VPI (high vs. low); (13) ER (positive vs. negative); (14) PR (positive vs. negative); (15) HER2 (positive vs. negative); (14) PR (positive vs. negative); (15) HER2 (positive vs. negative); (19) P-cadherin (positive vs. negative); (20) EGFR (positive vs. negative); (21) BLP1 (present vs. absent); (23) BLP3 (present vs. absent); (24) BLP4 (present vs. absent); (25) BLP5 (present vs. absent); (26) p53 (positive vs. negative); (27) FOXA1 (positive vs. negative).

Additional file 3: Fig. S2. Begg's test. (1) BCSS (univariate analysis); (2) BCSS (multivariate analysis); (3) OS (multivariate analysis); (4) DMFS (univariate analysis); (5) RFS (univariate analysis); (6) Age (age > 35 vs. age < 35); (7) TNM stage (grade III vs. grade I–II); (8) Tumor size (T_{2-4} vs. T_1); (9) Lymph node metastasis (N_+ vs. N_0); (10) IDC vs. DCIS; (11) IDC vs. ILC; (12) LVI (positive vs. negative); (13) BVI (positive vs. negative); (14) VPI (high vs. low); (15) ER (positive vs. negative); (16) PR (positive vs. negative); (17) Ki-67 (high vs. low); (18) TNBC vs. Non-TNBC; (19) P-cadherin (positive vs. negative); (20) EGFR (positive vs. negative); (21) BLP1 (present vs. absent); (22) BLP2 (present vs. absent); (23) BLP3 (present vs. absent); (24) BLP4 (present vs. absent); (25) FOXA1 (positive).

Additional file 4: Fig. S3. Egger's test. (1) BCSS (univariate analysis); (2) OS (multivariate analysis); (3) Age (age > 35 vs. age < 35); (4) TNM stage (grade III vs. grade I–II); (5) Tumor size (T_{2-4} vs. T_1); (6) Lymph node metastasis (N_+ vs. N_0); (7) IDC vs. DCIS; (8) IDC vs. ILC; (9) LVI (positive vs. negative); (10) VPI (high vs. low); (11) ER (positive vs. negative); (12) PR (positive vs. negative); (13) Ki-67 (high vs. low); (14) TNBC vs. Non-TNBC; (15) P-cadherin (positive vs. negative); (16) EGFR (positive vs. negative); (17) BLP1 (present vs. absent); (18) BLP2 (present vs. absent); (19) BLP3 (present vs. absent); (20) BLP4 (present vs. absent); (21) BLP5 (present vs. absent); (22) p53 (positive vs. negative).

Abbreviations

BC: Breast cancer; BCSS: Breast cancer-specific survival; BLP: Basal-like profiles; BVI: Blood vessel invasion; CBP: Core basal phenotype; CI: Confidence interval; CK5: Cytokeratin 5; CSC: Cancer stem cell; DCIS: Ductal carcinoma in situ; DMFS: Distant metastasis-free survival; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; ER: Estrogen receptor; FOXA1: Forkhead box protein A1; HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio; IBC: Invasive breast cancer; IDC: Invasive ductal carcinoma; IF: Intermediate filament; IHC: Immunohistochemistry; INPP4b: Inositol polyphosphate-4-phosphatase; LVI: Lymph vessel invasion; M: Multivariate analysis; MBC: Metastatic breast cancer; MT1: G-protein-coupled receptor for melatonin; MVD: Microvessel density; Oct-4: Octamer-binding transcription factor 4; OR: Odds ratio; OS: Overall survival; PFS: Progression-free survival; PR: Progesterone receptor; qPRT-PCR: Quantitative real time polymerase chain reaction; RCT: Randomized controlled trial; RFS: Recurrence-free survival; TNBC: Triple-negative breast cancer; TNM: Tumor node metastasis; U: Univariate analysis; VPI: Vascular proliferation index.

Acknowledgements

We sincerely thank Dr. Cindy Bi for her linguistic assistance during the preparation of this manuscript.

Authors' contributions

XYZ, WTG and KX contributed conception and design of the study, analysis and interpretation of data; XYZ, CSX, WTG, LC, KG, AZY and KX drafted the manuscript; KX contributed to study supervision. All authors contributed to manuscript revision. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used in this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Consent for publication

Not applicable.

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

Department of Cardiovascular Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.² Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.³ The Third Xiangya Hospital, Central South University, Changsha 410013, China.⁴ Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX 77030, USA.⁵ Department of Radiology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, China.⁶ Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.⁷ Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, China.⁸ Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.⁹ Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.¹⁰ Department of General Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. ¹¹ Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.

Received: 26 January 2020 Accepted: 10 May 2020 Published online: 14 May 2020

References

- DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.
- Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381–94.
- Fu NY, Nolan E, Lindeman GJ, Visvader JE. Stem cells and the differentiation hierarchy in mammary gland development. Physiol Rev. 2020;100(2):489–523.

- Fang Y, Zhang Q, Wang X, Yang X, Wang X, Huang Z, Jiao Y, Wang J. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells. Int J Oncol. 2016;48(3):1016–28.
- van Reesema LLS, Zheleva V, Winston JS, Jansen RJ, O'Connor CF, Isbell AJ, Bian M, Qin R, Bassett PT, Hinson VJ, et al. SIAH and EGFR, two RAS pathway biomarkers, are highly prognostic in locally advanced and metastatic breast cancer. EBioMedicine. 2016;11:183–98.
- 6. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care. 2011;6(2):136–41.
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23.
- 11. Matsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg. 2013;148(10):971–9.
- Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.
- Aebi S, Gelber S, Anderson SJ, Lang I, Robidoux A, Martin M, Nortier JW, Paterson AH, Rimawi MF, Canada JM, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15(2):156–63.
- Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.
- Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Fut Med Chem. 2015;7(12):1511–9.
- 16. Smith A, Farrah K. In: Gene expression profiling tests for breast cancer: a rapid qualitative review. Ottawa (ON); 2019.
- Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo X, Wei Q, Wang J, Xiong H, Chen C, Xu B, et al. Exosome: emerging biomarker in breast cancer. Oncotarget. 2017;8(25):41717–33.
- Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H, Kianmehr M. Breast cancer diagnosis: imaging techniques and biochemical markers. J Cell Physiol. 2018;233(7):5200–13.
- 19. Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1–23.
- Zhao ZW, Lu P, Zhang H, Xu HM, Gao NN, Li M, Liu CG. Nestin positively regulates the Wnt/beta-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res. 2014;16(4):408.
- Asleh K, Won JR, Gao DX, Voduc KD, Nielsen TO. Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. Breast Cancer Res Treat. 2018;168(1):107–15.
- De Lara S, Nyqvist J, Werner Rönnerman E, Helou K, Kenne Sarenmalm E, Einbeigi Z, Karlsson P, Parris TZ, Kovács A. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004–2014). BMC Cancer. 2019;19(1):187.
- Gao NN, Xu H, Liu CG, Xu HM, Chen GL, Wang XM, Li YY, Wang Y. Nestin: predicting specific survival factors for breast cancer. Tumor Biol. 2014;35(3):1751–5.
- 24. Kruger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, et al. Expression of Nestin

Page 16 of 17

associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci Rep. 2017;7(1):1089.

- Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, Lu P, Jin F. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep. 2012;39(5):5875–81.
- Liu CG, Chen B, Zhu J, Zhang RS, Yao F, Jin F, Xu HM, Lu P. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2010;101(3):815–9.
- Parry S, Savage K, Marchiò C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol. 2008;61(9):1045–50.
- Piras F, Ionta MT, Lai S, Perra MT, Atzori F, Minerba L, Pusceddu V, Maxia C, Murtas D, Demurtas P, et al. Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. Eur J Histochem. 2011;55(4):e39.
- 29. Guerette D, Khan PA, Savard PE, Vincent M. Molecular evolution of type VI intermediate filament proteins. BMC Evol Biol. 2007;7:164.
- Bernal A, Arranz L. Nestin-expressing progenitor cells: function, identity and therapeutic implications. Cell Mol Life Sci. 2018;75(12):2177–95.
- Cheng F, Eriksson JE. Intermediate filaments and the regulation of cell motility during regeneration and wound healing. Cold Spring Harb Perspect Biol. 2017;9(9):a022046.
- Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007;67(2):501–10.
- 33. Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015;106(7):803–11.
- Costa CD, Justo AA, Kobayashi PE, Story MM, Palmieri C, Laufer Amorim R, Fonseca-Alves CE. Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer. Int J Biochem Cell Biol. 2019;108:21–8.
- Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun. 2013;433(4):496–501.
- Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, Berman DM. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res. 2007;67(19):9199–206.
- Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–38.
- Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2015;31:28–35.
- Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34.
- 40. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. Mod Pathol. 2014;27(3):396–401.
- Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J, Lendahl U, Nakasho K, Sugihara A, Iwasaki T, Mano M, Yamada N, Yamashita K, et al. Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am J Pathol. 2001;158(3):817–23.
- Wang J, Cai J, Huang Y, Ke Q, Wu B, Wang S, Han X, Wang T, Wang Y, Li W, et al. Nestin regulates proliferation and invasion of gastrointestinal stromal tumor cells by altering mitochondrial dynamics. Oncogene. 2016;35(24):3139–50.
- Yamahatsu K, Matsuda Y, Ishiwata T, Uchida E, Naito Z. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis. Int J Oncol. 2012;40(5):1345–57.
- 44. Cros J, Sbidian E, Posseme K, Letierce A, Guettier C, Benoit G, Ferlicot S. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma. Virchows Arch. 2016;469(3):331–7.
- 45. Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, et al. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung Cancer. 2013;81(2):174–9.
- Zhao L, Li J, Liu M, Zhou H, Zou H, Wei Y, Sun K, Li G, Li S, Pang L. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis. Future Oncol. 2017;13(28):2555–70.
- Li S, Lai Y, Fan J, Shen C, Che G. Clinicopathological and prognostic significance of Nestin expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Clin Exp Med. 2017;17(2):161–74.

- Lv D, Lu L, Hu Z, Fei Z, Liu M, Wei L, Xu J. Nestin expression is associated with poor clinicopathological features and prognosis in glioma patients: an association study and meta-analysis. Mol Neurobiol. 2017;54(1):727–35.
- 49. Wu B, Sun C, Feng F, Ge M, Xia L. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J Exp Clin Cancer Res. 2015;34:44.
- Nowak A, Grzegrzolka J, Paprocka M, Piotrowska A, Rys J, Matkowski R, Dziegiel P. Nestin-positive microvessel density is an independent prognostic factor in breast cancer. Int J Oncol. 2017;51(2):668–76.
- Nowak A, Grzegrzółka J, Kmiecik A, Piotrowska A, Matkowski R, Dziggiel P. Role of nestin expression in angiogenesis and breast cancer progression. Int J Oncol. 2018;52(2):527–35.
- Asleh K, Lyck Carstensen S, Tykjaer Jorgensen CL, Burugu S, Gao D, Won JR, Jensen MB, Balslev E, Laenkholm AV, Nielsen DL, et al. Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: samples from the phase III SBG0102 clinical trial. Int J Cancer. 2019;144(10):2578–86.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- 54. Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, et al. Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther. 2015;14(1):307–14.
- Tampaki EC, Tampakis A, Nonni A, Kontzoglou K, Patsouris E, Kouraklis G. Nestin and cluster of differentiation 146 expression in breast cancer: predicting early recurrence by targeting metastasis? Tumour Biol. 2017;39(3):1010428317691181.
- Zhu J, Liu CG, Zhang RS, Lu Y, Jin F, Xu HM, Lu P. Relationship between nestin expression and other clinicopathological factors in breast cancer. J Chin Clin Med. 2009;4(11):622–5.
- Marmor S, Hui JYC, Huang JL, Kizy S, Beckwith H, Blaes AH, Rueth NM, Tuttle TM. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. 2017;123(16):3015–21.
- Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H. The neural stem/ progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem. 2010;58(8):721–30.
- Kruger K, Stefansson IM, Collett K, Arnes JB, Aas T, Akslen LA. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 2013;22(3):282–8.
- Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J, Weinberg RA. Upholding a role for EMT in breast cancer metastasis. Nature. 2017;547(7661):E1–3.

- Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P. Current insights into the association of Nestin with tumor angiogenesis. J BUON. 2015;20(3):699–706.
- 62. Wang Y, Li C, Li Y, Zhu Z. Involvement of breast cancer stem cells in tumor angiogenesis. Oncol Lett. 2017;14(6):8150–5.
- 63. Nowak A, Dziegiel P. Implications of nestin in breast cancer pathogenesis (Review). Int J Oncol. 2018;53(2):477–87.
- Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med. 2009;13(2):309–19.
- Mokry J, Cizkova D, Filip S, Ehrmann J, Osterreicher J, Kolar Z, English D. Nestin expression by newly formed human blood vessels. Stem Cells Dev. 2004;13(6):658–64.
- Liang ZW, Wang Z, Chen H, Li C, Zhou T, Yang Z, Yang X, Yang Y, Gao G, Cai W. Nestin-mediated cytoskeletal remodeling in endothelial cells: novel mechanistic insight into VEGF-induced cell migration in angiogenesis. Am J Physiol Cell Physiol. 2015;308(5):C349–58.
- Asleh-Aburaya K, Sheffield BS, Kos Z, Won JR, Wang XQ, Gao D, Wolber R, Gilks CB, Bernard PS, Chia SK, et al. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. Histopathology. 2017;70(2):185–94.
- Rogelsperger O, Ekmekcioglu C, Jager W, Klimpfinger M, Konigsberg R, Krenbek D, Sellner F, Thalhammer T. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009;46(4):422–32.
- Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192(1–2):147–56.
- Kiefer T, Ram PT, Yuan L, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat. 2002;71(1):37–45.
- Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118(3):451–8.
- Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol. 2008;154(6):1182–95.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

